Breaking News and Updates
- Abolition Of Work
- Alternative Medicine
- Artificial Intelligence
- Atlas Shrugged
- Ayn Rand
- Basic Income Guarantee
- Conscious Evolution
- Cosmic Heaven
- Designer Babies
- Ethical Egoism
- Fifth Amendment
- Fifth Amendment
- Financial Independence
- First Amendment
- Fiscal Freedom
- Food Supplements
- Fourth Amendment
- Fourth Amendment
- Free Speech
- Freedom of Speech
- Gene Medicine
- Genetic Engineering
- Germ Warfare
- Golden Rule
- Government Oppression
- High Seas
- Hubble Telescope
- Human Genetic Engineering
- Human Genetics
- Human Longevity
- Immortality Medicine
- Intentional Communities
- Life Extension
- Mars Colonization
- Mind Uploading
- Minerva Reefs
- Modern Satanism
- Moon Colonization
- New Utopia
- Personal Empowerment
- Political Correctness
- Politically Incorrect
- Post Human
- Post Humanism
- Private Islands
- Resource Based Economy
- Ron Paul
- Second Amendment
- Second Amendment
- Socio-economic Collapse
- Space Exploration
- Space Station
- Space Travel
- Teilhard De Charden
- The Singularity
- Tor Browser
- Transhuman News
- Victimless Crimes
- Virtual Reality
- Wage Slavery
- War On Drugs
- Zeitgeist Movement
The Evolutionary Perspective
Tag Archives: netherlands
Posted: December 10, 2016 at 1:44 pm
Human height or stature is the distance from the bottom of the feet to the top of the head in a human body, standing erect. It is measured using a stadiometer, usually in centimetres when using the metric system, or feet and inches when using the imperial system.
When populations share genetic background and environmental factors, average height is frequently characteristic within the group. Exceptional height variation (around 20% deviation from average) within such a population is sometimes due to gigantism or dwarfism, which are medical conditions caused by specific genes or endocrine abnormalities.
The development of human height can serve as an indicator of two key welfare components, namely nutritional quality and health. In regions of poverty or warfare, environmental factors like chronic malnutrition during childhood or adolescence may result in delayed growth and/or marked reductions in adult stature even without the presence of any of these medical conditions.
The study of height is known as auxology. Growth has long been recognized as a measure of the health of individuals, hence part of the reasoning for the use of growth charts. For individuals, as indicators of health problems, growth trends are tracked for significant deviations and growth is also monitored for significant deficiency from genetic expectations. Genetics is a major factor in determining the height of individuals, though it is far less influential in regard to differences among populations. Average height is relevant to the measurement of the health and wellness (standard of living and quality of life) of populations.
Attributed as a significant reason for the trend of increasing height in parts of Europe are the egalitarian populations where proper medical care and adequate nutrition are relatively equally distributed. Changes in diet (nutrition) and a general rise in quality of health care and standard of living are the cited factors in the Asian populations. Malnutrition including chronic undernutrition and acute malnutrition is known to have caused stunted growth in various populations. This has been seen in North Korea, parts of Africa, certain historical Europe, and other populations.Developing countries such as Guatemala have rates of stunting in children under 5 living as high as 82.2% in Totonicapn, and 49.8% nationwide.
Height measurements are by nature subject to statistical sampling errors even for a single individual.[clarification needed] In a clinical situation, height measurements are seldom taken more often than once per office visit, which may mean sampling taking place a week to several months apart. The smooth 50th percentile male and female growth curves illustrated above are aggregate values from thousands of individuals sampled at ages from birth to age 20. In reality, a single individual’s growth curve shows large upward and downward spikes, partly due to actual differences in growth velocity, and partly due to small measurement errors.
For example, a typical measurement error of plus or minus 0.5cm may completely nullify 0.5cm of actual growth resulting in either a “negative” 0.5cm growth (due to overestimation in the previous visit combined with underestimation in the latter), up to a 1.5cm growth (the first visit underestimating and the second visit overestimating) in the same elapsed time period between measurements. Note there is a discontinuity in the growth curves at age 2, which reflects the difference in recumbent length (with the child on his or her back), used in measuring infants and toddlers and standing height typically measured from age 2 onwards.
Height, like other phenotypic traits, is determined by a combination of genetics and environmental factors. A child’s height based on parental heights is subject to regression toward the mean, therefore extremely tall or short parents will likely have correspondingly taller or shorter offspring, but their offspring will also likely be closer to average height than the parents themselves. Genetic potential and a number of hormones, minus illness, is a basic determinant for height. Other factors include the genetic response to external factors such as diet, exercise, environment, and life circumstances.
Humans grow fastest (other than in the womb) as infants and toddlers, rapidly declining from a maximum at birth to roughly age 2, tapering to a slowly declining rate, and then during the pubertal growth spurt, a rapid rise to a second maximum (at around 1112 years for female, and 1314 years for male), followed by a steady decline to zero. On average, female growth speed trails off to zero at about 15 or 16 years, whereas the male curve continues for approximately 3 more years, going to zero at about 1820. These are also critical periods where stressors such as malnutrition (or even severe child neglect) have the greatest effect.
Moreover, the health of a mother throughout her life, especially during her critical period and pregnancy, has a role. A healthier child and adult develops a body that is better able to provide optimal prenatal conditions. The pregnant mother’s health is important for herself but also for the fetus as gestation is itself a critical period for an embryo/fetus, though some problems affecting height during this period are resolved by catch-up growth assuming childhood conditions are good. Thus, there is a cumulative generation effect such that nutrition and health over generations influences the height of descendants to varying degrees.
The age of the mother also has some influence on her child’s height. Studies in modern times have observed a gradual increase in height with maternal age, though these early studies suggest that trend is due to various socio-economic situations that select certain demographics as being more likely to have a first birth early in the mother’s life. These same studies show that children born to a young mother are more likely to have below-average educational and behavioural development, again suggesting an ultimate cause of resources and family status rather than a purely biological explanation.
It has been observed that first-born males are shorter than later-born males. However, more recently the reverse observation was made. The study authors suggest that the cause may be socio-economic in nature.
The precise relationship between genetics and environment is complex and uncertain. Differences in human height is 60%80% heritable, according to several twin studies and has been considered polygenic since the Mendelian-biometrician debate a hundred years ago. A genome-wide association (GWA) study of more than 180,000 individuals has identified hundreds of genetic variants in at least 180 loci associated with adult human height. The number of individuals has since been expanded to 253,288 individuals and the number of genetic variants identified is 697 in 423 genetic loci. In a separate study of body proportion using sitting-height ratio, it reports that these 697 variants can be partitioned into 3 specific classes, (1) variants that primarily determine leg length, (2) variants that primarily determine spine and head length, or (3) variants that affect overall body size. This gives insights into the biological mechanisms underlying how these 697 genetic variants affect overall height.
The effect of environment on height is illustrated by studies performed by anthropologist Barry Bogin and coworkers of Guatemala Mayan children living in the United States. In the early 1970s, when Bogin first visited Guatemala, he observed that Mayan Indian men averaged only 157.5 centimetres (5ft 2in) in height and the women averaged 142.2 centimetres (4ft 8in). Bogin took another series of measurements after the Guatemalan Civil War, during which up to a million Guatemalans fled to the United States. He discovered that Maya refugees, who ranged from six to twelve years old, were significantly taller than their Guatemalan counterparts. By 2000, the American Maya were 10.24cm (4.03in) taller than the Guatemalan Maya of the same age, largely due to better nutrition and health care. Bogin also noted that American Maya children had relatively longer legs, averaging 7.02cm (2.76in) longer than the Guatemalan Maya (a significantly lower sitting height ratio).
The Nilotic peoples of Sudan such as the Shilluk and Dinka have been described as some of the tallest in the world. Dinka Ruweng males investigated by Roberts in 195354 were on average 181.3 centimetres (5ft 1112in) tall, and Shilluk males averaged 182.6 centimetres (6ft 0in). The Nilotic people are characterized as having long legs, narrow bodies and short trunks, an adaptation to hot weather. However, male Dinka and Shilluk refugees measured in 1995 in Southwestern Ethiopia were on average only 1.764 m and 1.726 m tall, respectively. As the study points out, Nilotic people “may attain greater height if priviledged with favourable environmental conditions during early childhood and adolescence, allowing full expression of the genetic material.” Before fleeing, these refugees were subject to privation as a consequence of the succession of civil wars in their country from 1955 to the present. The tallest living married couple are ex-basketball players Yao Ming and Ye Li (both of China) who measure 228.6cm (7 ft 11 in) and 190.5cm (6 ft 3 in) respectively, giving a combined height of 419.1cm (13 ft 9 in). They married in Shanghai, China, on 6 August 2007.
In Tibet, the khampas are known for their great height. Khampa males are on average 180cm tall (5ft 11 in).
The people of the Dinaric Alps (mainly North Albanians and South Slavs) are on record as being the tallest in the world, with a male average height of 185.6cm (6ft 1.1 in) and female average height of 170.9cm (5ft 7.3 in).
Growth in stature, determined by its various factors, results from the lengthening of bones via cellular divisions chiefly regulated by somatotropin (human growth hormone (hGH)) secreted by the anterior pituitary gland. Somatotropin also stimulates the release of another growth inducing hormone Insulin-like growth factor 1 (IGF-1) mainly by the liver. Both hormones operate on most tissues of the body, have many other functions, and continue to be secreted throughout life; with peak levels coinciding with peak growth velocity, and gradually subsiding with age after adolescence. The bulk of secretion occurs in bursts (especially for adolescents) with the largest during sleep.
The majority of linear growth occurs as growth of cartilage at the epiphysis (ends) of the long bones which gradually ossify to form hard bone. The legs compose approximately half of adult human height, and leg length is a somewhat sexually dimorphic trait, with men having proportionately longer legs. Some of this growth occurs after the growth spurt of the long bones has ceased or slowed. The majority of growth during growth spurts is of the long bones. Additionally, the variation in height between populations and across time is largely due to changes in leg length. The remainder of height consists of the cranium. Height is sexually dimorphic and statistically it is more or less normally distributed, but with heavy tails. It has been shown that a log-normal distribution fits the data equally well, besides guaranteeing a non-negative lower confidence limit, which could otherwise attain a non-physical negative height value for arbitrarily large confidence levels.
Most intra-population variance of height is genetic. Short stature and tall stature are usually not a health concern. If the degree of deviation from normal is significant, hereditary short stature is known as familial short stature and tall stature is known as familial tall stature. Confirmation that exceptional height is normal for a respective person can be ascertained from comparing stature of family members and analyzing growth trends for abrupt changes, among others. There are, however, various diseases and disorders that cause growth abnormalities.
Most notably, extreme height may be pathological, such as gigantism resulting from childhood hyperpituitarism, and dwarfism which has various causes. Rarely, no cause can be found for extreme height; very short persons may be termed as having idiopathic short stature. The United States Food and Drug Administration (FDA) in 2003 approved hGH treatment for those 2.25 standard deviations below the population mean (approximately the lowest 1.2% of the population). An even rarer occurrence, or at least less used term and recognized “problem”, is idiopathic tall stature.
If not enough growth hormone is produced and/or secreted by the pituitary gland, then a patient with growth hormone deficiency can undergo treatment. This treatment involves the injection of pure growth hormone into thick tissue to promote growth.
Certain studies have shown that height is a factor in overall health while some suggest tallness is associated with better cardiovascular health and shortness with longevity. Cancer risk has also been found to grow with height.
Nonetheless, modern westernized interpretations of the relationship between height and health fail to account for the observed height variations worldwide. Cavalli-Sforza and Cavalli-Sforza note that variations in height worldwide can be partly attributed to evolutionary pressures resulting from differing environments. These evolutionary pressures result in height related health implications. While tallness is an adaptive benefit in colder climates such as found in Europe, shortness helps dissipate body heat in warmer climatic regions. Consequently, the relationships between health and height cannot be easily generalized since tallness and shortness can both provide health benefits in different environmental settings.
At the extreme end, being excessively tall can cause various medical problems, including cardiovascular problems, because of the increased load on the heart to supply the body with blood, and problems resulting from the increased time it takes the brain to communicate with the extremities. For example, Robert Wadlow, the tallest man known to verifiable history, developed trouble walking as his height increased throughout his life. In many of the pictures of the later portion of his life, Wadlow can be seen gripping something for support. Late in his life, although he died at age 22, he had to wear braces on his legs and walk with a cane; and he died after developing an infection in his legs because he was unable to feel the irritation and cutting caused by his leg braces.
Sources are in disagreement about the overall relationship between height and longevity. Samaras and Elrick, in the Western Journal of Medicine, demonstrate an inverse correlation between height and longevity in several mammals including humans.
Women whose height is under 150cm (4ft 11in) may have a small pelvis, resulting in such complications during childbirth as shoulder dystocia.
A study done in Sweden in 2005 has shown that there is a strong inverse correlation between height and suicide among Swedish men.
A large body of human and animal evidence indicates that shorter, smaller bodies age slower, and have fewer chronic diseases and greater longevity. For example, a study found eight areas of support for the “smaller lives longer” thesis. These areas of evidence include studies involving longevity, life expectancy, centenarians, male vs. female longevity differences, mortality advantages of shorter people, survival findings, smaller body size due to calorie restriction, and within species body size differences. They all support the conclusion that smaller individuals live longer in healthy environments and with good nutrition. However, the difference in longevity is modest. Several human studies have found a loss of 0.5 year/centimeter of increased height (1.2 yr/inch). But these findings do not mean that all tall people die young. Many live to advanced ages and some become centenarians.
There is a large body of research in psychology, economics, and human biology that has assessed the relationship between several seemingly innocuous physical features (e.g., body height) and occupational success. The correlation between height and success was explored decades ago. Shorter people are considered to have an advantage in certain sports (e.g., gymnastics, race car driving, etc.), whereas in many other sports taller people have a major advantage. In most occupational fields, body height is not relevant to how well people are able to perform, but nonetheless has been found to correlate with their success in several studies, although there may be other factors such as gender or socioeonomic status that explain this.
A demonstration of the height-success association can be found in the realm of politics. In the United States presidential elections, the taller candidate won 22 out of 25 times in the 20th century. Nevertheless, Ignatius Loyola, founder of the Jesuits, was 150cm (4ft 11in) and several prominent world leaders of the 20th century, such as Vladimir Lenin, Benito Mussolini, Nicolae Ceauescu and Joseph Stalin were of below average height. These examples, however, were all before modern forms of multi-media, i.e., television, which may further height discrimination in modern society. Further, growing evidence suggests that height may be a proxy for confidence, which is likewise strongly correlated with occupational success.
In the eighteenth and nineteenth centuries, people of European descent in North America were far taller than those in Europe and were the tallest in the world. The original indigenous population of Plains Native Americans was also among the tallest populations of the world at the time.
In the late nineteenth century, the Netherlands was a land renowned for its short population, but today its population is among the world’s tallest with young men averaging 183.8cm (6ft 0.4in) tall.
According to a study by economist John Komlos and Francesco Cinnirella, in the first half of the 18th century, the average height of an English male was 165cm (5ft 5 in), and the average height of an Irish male was 168cm (5ft 6 in). The estimated mean height of English, German, and Scottish soldiers was 163.6cm 165.9cm (5ft 4.4 in 5ft 5.3 in) for the period as a whole, while that of Irish was 167.9cm (5ft 6.1 in). The average height of male slaves and convicts in North America was 171cm (5ft 7 in).
American-born colonial soldiers of the late 1770s were on average more than 7.6cm (3 inches) taller than their English counterparts who served in Royal Marines at the same time.
Average height of Americans and Europeans decreased during periods of rapid industrialization, possibly due to rapid population growth and increased economic inequality. In early 19th century England, the difference between average height of English upper class youth (students of Sandhurst Military Academy) and English lower class youth (Marine Society boys) reached 22cm (8.7in), the highest that has been observed.
Data derived from burials show that before 1850, the mean stature of males and females in Leiden, Netherlands was respectively 166.7cm (5ft 5.6 in) and 156.7cm (5ft 1.7 in). The average height of 19-year-old Dutch orphans in 1865 was 160cm (5ft 3 in).
According to a study by J.W. Drukker and Vincent Tassenaar, the average height of Dutch decreased from 1830 to 1857, even while Dutch real GNP per capita was growing at an average rate of more than 0.5 percent per year. The worst decline were in urban areas that in 1847, the urban height penalty was 2.5cm (1in). Urban mortality was also much higher than rural regions. In 1829, the average urban and rural Dutchman was 164cm (5ft 4.6 in). By 1856, the average rural Dutchman was 162cm (5ft 3.8 in) and urban Dutchman was 158.5cm (5ft 2.4 in).
A 2004 report citing a 2003 UNICEF study on the effects of malnutrition in North Korea, due to “successive famines,” found young adult males to be significantly shorter.[specify] In contrast South Koreans “feasting on an increasingly Western-influenced diet,” without famine, were growing taller. The height difference is minimal for Koreans over 40, who grew up at a time when economic conditions in the North were roughly comparable to those in the South, while height disparities are most acute for Koreans who grew up in the mid-1990s a demographic in which South Koreans are about 12cm (4.7in) taller than their North Korean counterparts as this was a period during which the North was affected by a harsh famine. A study by South Korean anthropologists of North Korean children who had defected to China found that 18-year-old males were 5inches (13cm) shorter than South Koreans their age due to malnutrition.
The tallest living man is Sultan Ksen of Turkey, at 251cm (8ft 3in). The tallest man in modern history was Robert Pershing Wadlow (19181940), from Illinois, in the United States, who was 272cm (8ft 11in) at the time of his death. The tallest woman in medical history was Zeng Jinlian of Hunan, China, who stood 248cm (8ft 112in) when she died at the age of 17. The shortest adult human on record was Chandra Bahadur Dangi of Nepal at 54.6cm (1ft 912in).
Adult height between populations often differs significantly. For example, the average height of women from the Czech Republic is greater than that of men from Malawi. This may be caused by genetic differences, childhood lifestyle differences (nutrition, sleep patterns, physical labor), or both.
Depending on sex, genetic and environmental factors, shrinkage of stature may begin in middle age in some individuals but tends to be universal in the extremely aged. This decrease in height is due to such factors as decreased height of inter-vertebral discs because of desiccation, atrophy of soft tissues and postural changes secondary to degenerative disease.
As with any statistical data, the accuracy of such data may be questionable for various reasons:
The rest is here:
Human height – Wikipedia
Posted: November 23, 2016 at 10:05 pm
Voluntary euthanasia is the practice of ending a life in a painless manner. Voluntary euthanasia (VE) and physician-assisted suicide (PAS) have been the focus of great controversy in recent years.
As of 2009, some forms of voluntary euthanasia are legal in Belgium,Luxembourg, the Netherlands,Switzerland, and Canada.
Voluntary refusal of food and fluids (VRFF) or Patient Refusal of Nutrition and Hydration (PRNH) is bordering on euthanasia. Some authors classify it as a form of passive euthanasia, while others treat it separately because it is treated differently from legal point of view and often perceived as a more ethical option. VRFF is sometimes suggested as a legal alternative to euthanasia in jurisdictions disallowing euthanasia.
Assisted suicide is a practice in which a person receives assistance in bringing about their death, typically people suffering from a severe physical illness, in which the final step in the process is actively performed by the person concerned. In physician-assisted suicide (also called physician aid-in-dying or PAD) a physician knowingly provides a competent but suffering patient, upon the patient’s request, with the means by which the patient intends to end his or her own life. Assisted suicide is contrasted with “active euthanasia” when the difference between providing the means and actively administering lethal medicine is considered important. For example, Swiss law allows assisted suicide while all forms of active euthanasia (like lethal injection) remain prohibited.
The term euthanasia comes from the Greek words “eu”-meaning good and “thanatos”-meaning death, which combined means well-death or “dying well”. Hippocrates mentions euthanasia in the Hippocratic Oath, which was written between 400 and 300 BC The original Oath states: To please no one will I prescribe a deadly drug nor give advice which may cause his death. Despite this, the ancient Greeks and Romans generally did not believe that life needed to be preserved at any cost and were, in consequence, tolerant of suicide in cases where no relief could be offered to the dying or, in the case of the Stoics and Epicureans, where a person no longer cared for his life.
English Common Law from the 14th century until the middle of the last century made suicide a criminal act in England and Wales. Assisting others to kill themselves remains illegal in that jurisdiction. However, in the 16th century, Thomas More, considered a saint by Roman Catholics, described a utopian community and envisaged such a community as one that would facilitate the death of those whose lives had become burdensome as a result of “torturing and lingering pain”, see The meaning of the work.
Since the 19th century, euthanasia has sparked intermittent debates and activism in North America and Europe. According to medical historian Ezekiel Emanuel, it was the availability of anesthesia that ushered in the modern era of euthanasia. In 1828, the first known anti-euthanasia law in the United States was passed in the state of New York, with many other localities and states following suit over a period of several years. After the Civil War, voluntary euthanasia was promoted by advocates, including some doctors. Support peaked around the start of the 20th century in the US and then grew again in the 1930s.
In an article in the Bulletin of the History of Medicine, Brown University historian Jacob M. Appel documented extensive political debate over legislation to legalize physician-assisted suicide in both Iowa and Ohio in 1906. Appel indicates social activist Anna S. Hall was the driving force behind this movement. According to historian Ian Dowbiggin, leading public figures, including Clarence Darrow and Jack London, advocated for the legalization of euthanasia.
Euthanasia societies[which?] were formed in England in 1935 and in the USA in 1938 to promote euthanasia. Although euthanasia legislation did not pass in the USA or England, in 1937, doctor-assisted euthanasia was declared legal in Switzerland as long as the doctor ending the life had nothing to gain. During this same era, US courts tackled cases involving critically ill people who requested physician assistance in dying as well as mercy killings, such as by parents of their severely disabled children.
During the post-war period, prominent proponents of euthanasia included Glanville Williams (The Sanctity of Life and the Criminal Law) and clergyman Joseph Fletcher (“Morals and medicine”). By the 1960s, advocacy for a right-to-die approach to voluntary euthanasia increased.
In 1996, the world’s first euthanasia legislation, the Rights of the Terminally Ill Act 1996, was passed in the Northern Territory of Australia. Four patients died through assisted suicide under the Act, using a device designed by Dr Philip Nitschke. The legislation was overturned by Australias Federal Parliament in 1997. In response to the overturning of the Act, Nitschke founded EXIT International. In 2009, an Australian quadriplegic was granted the right to refuse sustenance and be allowed to die. The Supreme Court of Western Australia ruled that it was up to Christian Rossiter, aged 49, to decide if he was to continue to receive medical care (tube feeding) and that his carers had to abide by his wishes. Chief Justice Wayne Martin also stipulated that his carers, Brightwater Care, would not be held criminally responsible for following his instructions. Rossiter died on 21 September 2009 following a chest infection.
In 1957 in Britain, Judge Devlin ruled in the trial of Dr John Bodkin Adams that causing death through the administration of lethal drugs to a patient, if the intention is solely to alleviate pain, is not considered murder even if death is a potential or even likely outcome. In 1993, the Netherlands decriminalized doctor-assisted suicide, and in 2002, restrictions were loosened. During that year, physician-assisted suicide was approved in Belgium. Belgium’s at the time most famous author Hugo Claus, suffering from Alzheimer’s disease, was among those that asked for euthanasia. He died in March 2008, assisted by an Antwerp doctor.
A key turning point in the debate over voluntary euthanasia (and physician assisted dying), at least in the United States, was the public furor over the Karen Ann Quinlan case. The Quinlan case paved the way for legal protection of voluntary passive euthanasia. In 1977, California legalized living wills and other states soon followed suit.
In 1980 the Hemlock Society USA was founded in Santa Monica by Derek Humphry. It was the first group in America to provide information to the terminally ill in case they wanted a hastened death. Hemlock also campaigned and partially financed drives to reform the law. In 2003 Hemlock was merged with End of Life Choices, which changed its name to Compassion and Choices.
In 1990, Dr. Jack Kevorkian, a Michigan physician, became famous for educating and assisting people in committing physician-assisted suicide, which resulted in a Michigan law against the practice in 1992. Kevorkian was tried and convicted in 1999 for a murder displayed on television. Also in 1990, the Supreme Court approved the use of non-active euthanasia.
In 1994, Oregon voters approved the Death with Dignity Act, permitting doctors to assist terminal patients with six months or less to live to end their lives. The U.S. Supreme Court allowed such laws in 1997. The Bush administration failed in its attempt to use drug law to stop Oregon in 2001, in the case Gonzales v. Oregon.
In 2005, amid U.S. government roadblocks and controversy, Terri Schiavo, a Floridian who had been in a vegetative state since 1990, had her feeding tube removed. Her husband had won the right to take her off life support, which he claimed she would want but was difficult to confirm as she had no living will and the rest of her family claimed otherwise.
In November 2008, Washington Initiative 1000 made Washington the second U.S. state to legalize physician-assisted suicide.
Euthanasia is a criminal offense in China. For example, in Shanghai a 67-year-old man was sentenced to 5 years in prison when he euthanized his 92-year-old mother when she emerged from a hospital procedure only able to move one finger and one toe. The sentence was considered lenient, because he had displayed filial piety toward his mother.
While active euthanasia remains illegal in China, it is gaining increasing acceptance among doctors and the general populace.
In Hong Kong, support for euthanasia among the general public is higher among those who put less importance on religious belief, those who are non-Christian, those who have higher family incomes, those who have more experience in taking care of terminally ill family members, and those who are older.
Since World War II, the debate over euthanasia in Western countries has centered on voluntary euthanasia within regulated health care systems. In some cases, judicial decisions, legislation, and regulations have made voluntary euthanasia an explicit option for patients and their guardians. Proponents and critics of such voluntary euthanasia policies offer the following reasons for and against official voluntary euthanasia policies:
Proponents of voluntary euthanasia emphasize that choice is a fundamental principle for liberal democracies and free market systems.
The pain and suffering a person feels during a disease, even with pain relievers, can be incomprehensible to a person who has not gone through it. Even without considering the physical pain, it is often difficult for patients to overcome the emotional pain of losing their independence.
Those who witness others die are “particularly convinced” that the law should be changed to allow assisted death.
Today in many countries there is a shortage of hospital space. Medical personnel and hospital beds could be used for people whose lives could be saved instead of continuing the lives of those who want to die, thus increasing the general quality of care and shortening hospital waiting lists. It is a burden to keep people alive past the point they can contribute to society, especially if the resources used could be spent on a curable ailment.
Critics argue that voluntary euthanasia could unduly compromise the professional roles of health care employees, especially doctors. They point out that European physicians of previous centuries traditionally swore some variation of the Hippocratic Oath, which in its ancient form excluded euthanasia: “To please no one will I prescribe a deadly drug nor give advice which may cause his death..” However, since the 1970s, this oath has largely fallen out of use.
Some people, including many Christians, consider euthanasia of some or all types to be morally unacceptable. This view usually treats euthanasia to be a type of murder and voluntary euthanasia as a type of suicide, the morality of which is the subject of active debate.
If there is some reason to believe the cause of a patient’s illness or suffering is or will soon be curable, the correct action is sometimes considered to attempt to bring about a cure or engage in palliative care.
Feasibility of implementation: Euthanasia can only be considered “voluntary” if a patient is mentally competent to make the decision, i.e., has a rational understanding of options and consequences. Competence can be difficult to determine or even define.
Consent under pressure: Given the economic grounds for voluntary euthanasia, critics of voluntary euthanasia are concerned that patients may experience psychological pressure to consent to voluntary euthanasia rather than be a financial burden on their families. Even where health costs are mostly covered by public money, as in most developed countries, voluntary euthanasia critics are concerned that hospital personnel would have an economic incentive to advise or pressure people toward euthanasia consent.
Non-voluntary euthanasia is sometimes cited as one of the possible outcomes of the slippery slope argument, in which it is claimed that permitting voluntary euthanasia to occur will lead to the support and legalization of non-voluntary and involuntary euthanasia.
The right to life movement opposes voluntary euthanasia.
Euthanasia brings about many ethical issues regarding a patients death. Some physicians say euthanasia is a rational choice for competent patients who wish to die to escape unbearable suffering.
Physicians who are in favor of euthanasia state that to keep euthanasia or physician-assisted suicide (PAS) illegal is a violation of patient freedoms. They believe that any competent terminally-ill patient should have the right to choose death or refuse life-saving treatment. Suicide and assistance from their physician is seen as the only option those patients have. With the suffering and the knowledge from the doctor, this may also suggest that PAS is a humane answer to the excruciating pain.
An argument against PAS is the violation of the Hippocratic oath that some doctors take. The Hippocratic oath states “I will not give a lethal drug to anyone if I am asked, nor will I advise such a plan”.
Another reason for prohibiting PAS and euthanasia is the option of abusing PAS if it were to become legal. Poor or uninsured patients may not have the money or no access to proper care will have limited options, and they could be pressured towards assisted death.
During the 20th century, efforts to change government policies on euthanasia have met limited success in Western countries. Euthanasia policies have also been developed by a variety of NGOs, most notably medical associations and advocacy organizations.
There are many different religious views among on the issue of voluntary euthanasia, although many moral theologians are critical of the procedure.
Euthanasia can be accomplished either through an oral, intravenous, or intramuscular administration of drugs, or by oxygen deprivation (anoxia), as in some euthanasia machines. In individuals who are incapable of swallowing lethal doses of medication, an intravenous route is preferred. The following is a Dutch protocol for parenteral (intravenous) administration to obtain euthanasia:
Intravenous administration is the most reliable and rapid way to accomplish euthanasia. A coma is first induced by intravenous administration of 20mg/kg sodium thiopental (Nesdonal) in a small volume (10 ml physiological saline). Then a triple intravenous dose of a non-depolarizing neuromuscular muscle relaxant is given, such as 20mg pancuronium bromide (Pavulon) or 20mg vecuronium bromide (Norcuron). The muscle relaxant should preferably be given intravenously, in order to ensure optimal availability. Only for pancuronium bromide (Pavulon) are there substantial indications that the agent may also be given intramuscularly in a dosage of 40mg.
With regards to voluntary euthanasia, many people argue that ‘equal access’ should apply to access to suicide as well, so therefore disabled people who cannot kill themselves should have access to voluntary euthanasia.
Apart from The Old Law, a 17th-century tragicomedy written by Thomas Middleton, William Rowley, and Philip Massinger, one of the early books to deal with euthanasia in a fictional context is Anthony Trollope’s 1882 dystopian novel, The Fixed Period. Ricarda Huch’s novel The Deruga Case (1917) is about a physician who is acquitted after performing euthanasia on his dying ex-wife.
“Quality of Mercy” in The Prosecution Rests is a fable exploring the facets of aging, Alzheimer’s disease, and euthanasia. The story line makes no judgement but frees the reader to decide.
The plot of Christopher Buckley’s 2007 novel Boomsday involves the use of ‘Voluntary euthanasia’ of seniors as a political ploy to stave of the insolvency of social security as more and more of the aging US population reaches retirement age.
The films Children of Men and Soylent Green depict instances of government-sponsored euthanasia in order to strengthen their dystopian themes. The protagonist of the film Johnny Got His Gun is a brutally mutilated war veteran whose request for euthanasia furthers the work’s anti-war message. The recent films Mar Adentro and Million Dollar Baby argue more directly in favor of euthanasia by illustrating the suffering of their protagonists. These films have provoked debate and controversy in their home countries of Spain and the United States respectively.
In March 2010, the PBS Frontline TV program in the United States showed a documentary called “The Suicide Tourist” which told the story of Professor Craig Ewert, his family, and the Swiss group Dignitas, and their decision to commit assisted suicide in Switzerland after he was diagnosed and suffering with ALS (Lou Gehrig’s Disease).
Thrash metal band Megadeth’s 1994 album Youthanasia (the title is a pun on euthanasia) implies that society is euthanizing its youth.
The documentary film How to Die in Oregon follows the lives of select terminally ill individuals who weigh the options of continuing to live and euthanasia. This film employs emotional appeal to the audience on the controversial topic of voluntary euthanasia.
Go here to see the original:
Posted: at 10:04 pm
Offshore (Engels: weg van de kust), ook wel als buitengaats of aflandig aangeduid, is de aanduiding van activiteiten die plaatsvinden op enige afstand van de kust, meestal gericht op exploratie en winning van olie en gas, maar in toenemende mate ook van windenergie en aquacultuur. Het is onder te verdelen in een mijnbouwdeel met olie- en gasplatforms en een maritiem deel, zoals duikondersteuningsschepen, platformbevoorradingsschepen, pijpenleggers en kraanschepen. De offshore begon vlak na de Tweede Wereldoorlog, aanvankelijk vooral in de Golf van Mexico in ondiep water. Tegenwoordig vindt onder druk van de afnemende beschikbare hoeveelheid olie dicht bij de kust een verschuiving plaats naar diep water.
Onder offshoretechniek wordt verstaan het ontwerpen, construeren en plaatsen van kunstwerken die dienstdoen bij industrile processen of publieke voorzieningen en de exploratie en winning van olie en gas op zee.
Exploratie bestaat uit meerdere fases. Aanvankelijk begon dit met geologische opsporing, waarbij vooral oppervlaktegegevens worden genterpreteerd. In het midden van de jaren twintig van de twintigste eeuw waren alle aan de oppervlakte liggende velden in de Verenigde Staten in kaart gebracht en had men andere methoden nodig om dieper gelegen velden te vinden. De methodes van deze geofysische opsporing die op zee bruikbaar zijn, zijn seismiek, gravimetrie en magnetisch onderzoek, dat wordt uitgevoerd met onderzoeksvaartuigen. Bij veelbelovende aanwijzingen wordt een exploratieconcessie aangevraagd om daarna proefboringen te doen. Deze exploratieboring moet uitsluitsel geven of een formatie werkelijk olie of gas bevat. Dit vakgebied is de petrofysica. Deze proefboringen worden in ondiep water uitgevoerd door hefeilanden en in diep water door boorschepen en half-afzinkbare platforms. Met behulp van structurele geologie wordt daarna de omvang van een olie- of gasvoorkomen vastgesteld. Als die voldoende is, kan een oliemaatschappij besluiten tot winning over te gaan. Hiervoor worden productieputten geboord.
Al aan het einde van de negentiende eeuw werd in Californi, waar veel olie op natuurlijke wijze naar de oppervlakte lekt (seeps), net uit de kust gebouwd vanaf pieren in olievelden aan de wal die zich voortzetten in zee. Begin twintigste eeuw werd ook begonnen met boren naar vooral gas in het Eriemeer, voornamelijk aan de Canadese kant. Enkele jaren later werd ook in het Caddomeer op de grens van Louisiana en Texas geboord vanaf houten platforms. In Venezuela werd vanaf de jaren twintig in het Meer van Maracaibo naar olie geboord, terwijl in de jaren dertig werd begonnen in de Kaspische Zee.
In de jaren twintig van de twintigste eeuw gebruikte men in de moerassen, meren en baaien van Louisiana de houten platforms om vanaf te boren. In deze overgangszone onder invloed van het getij begon Chevron gebruik te maken van bakken om het materiaal sneller te kunnen verplaatsen. Ter plekke liet men deze afzinken tot op de bodem van het ondiepe water om daarna te boren. De eerste bak die op deze manier te werk ging, was de Giliasso, genoemd naar Louis Giliasso die dit idee had ontwikkeld. De stabiliteit van deze bakken was echter beperkt, zodat de waterdiepte waarin dit gebruikt kon worden, beperkt was tot zo’n drie meter. In 1937 lieten Pure Oil en Superior Oil door Brown & Root het tot dan toe grootste platform van de Golfkust bouwen, nog steeds van hout. In 1946 bouwde Brown & Root een platform met stalen palen voor Magnolia Petroleum.
Dit was echter allemaal dicht bij de kust. Begin 1947 liet Superior 18 mijl uit de kust bij Vermilion Parish een platform bouwen. Een platform van Kerr-McGee wist echter in oktober enkele maanden voor Superior een olieput in productie te brengen. Dit gebeurde in Ship Shoal Block 32 voor de kust van Louisiana in de Golf van Mexico met Rig 16 aan boord van de Frank Phillips. Dit wordt wel beschouwd als het begin van de offshore-industrie.
In de jaren vijftig verplaatste de boring zich naar steeds dieper water en werden eerst bakken en tenders kleine scheepsvormige bakken gebruikt. Later werden platforms gebruikt die naar locatie werden gesleept en daarna afgezonken tot ze rustten op de zeebodem. Deze afzinkers waren een idee van John T. Hayward die voor Barnsdall Oil & Gas werkte. Hierbij werden de voordelen van bakken gecombineerd met die van platforms op palen. Door op de bakken kolommen te plaatsen met daarop het werkdek was de invloed van de golven beperkt en had men toch een verplaatsbaar platform. De eerste was de Breton Rig 20, die in waterdieptes tot 6 meter kon werken. Nadat olie-exploratie in de Golf stil had gelegen van 1950 tot 1953 vanwege de Tidelands controversy, begon Alden J. Laborde zijn eigen bedrijf Odeco om met financiering van Murphy Oil een nieuw type afzinker te bouwen dat geschikt was voor dieper water. Dit platform, de Mr. Charlie, kon in waterdieptes tot 12 meter werken. Dit rechthoekige type werd snel populair, maar ook snel daarna vervangen door de ultieme afzinker het kolomgestabiliseerde platform of flessentype, waarvan de eerste Rig 46 was van Kerr-McGee in 1956. Dit type kon boren in waterdieptes tot 55 meter.
In waterdieptes verder uit de kust konden ook deze platforms echter niet meer aan het werk. Al in de jaren dertig werd gebruikgemaakt van hefeilanden voor constructiewerkzaamheden op zee en ook bij de landingen in Normandi tijdens D-Day werd hier gebruik van gemaakt. In 1950 liet Leon B. DeLong een aantal hefeilanden bouwen voor radarinstallaties in waterdieptes van 20 meter. De mobiliteit was een groot voordeel en in 1954 lieten meerdere bedrijven hefeilanden bouwen, waaronder Rig No. 51 van The Offshore Company en Mr. Gus van Glasscock Drilling. Tegenwoordig kan er met hefeilanden in waterdieptes tot 120 meter geboord worden.
De eerste half-afzinkbare platform werd per ongeluk uitgevonden in 1961. Blue Water Drilling Company bezat de uit vier kolommen bestaande afzinkbare Blue Water Rig No.1, gebouwd in 1957. Ze gebruikten deze voor Shell Oil Company in de Golf van Mexico om in 25 meter diep water te boren met het onderste deel van de romp op de bodem. Omdat de pontons niet genoeg drijfvermogen hadden om het totale gewicht van het rig te ondersteunen werd het naar locatie gesleept op een diepgang tussen de bovenzijde van de pontons en de onderzijde van het dek. Men merkte op dat de bewegingen veroorzaakt door de deining op deze diepgang gering waren vergeleken met conventionele schepen. Blue Water Drilling en Shell besloten gezamenlijk het platform drijvend te gebruiken voor boring.
Sindsdien worden half-afzinkbare platforms specifiek ontworpen voor de offshore industrie. In 1963 werd het eerste echte half-afzinkbare platform gebouwd, de Ocean Driller van Odeco. De grootste ramp met een half-afzinkbaar platform was het kapseizen van de Ocean Ranger, ook van Odeco, tijdens een storm op 15 februari 1982 op de Atlantische Oceaan, 315 kilometer zuidoost van St. John’s bij de Grand Banks, waarbij alle 84 bemanningsleden omkwamen.
Waar de waterdiepte in de Golf van Mexico geleidelijk toeneemt, is deze bij Californi al dicht bij de kust te diep voor platforms die op de zeebodem rusten. Om ook in deze wateren te kunnen boren, begon Shell in 1948 een consortium met Continental, Union en Superior (CUSS). In 1953 begonnen ze met proefboringen vanaf de verbouwde Submarex. Hierbij werd geboord vanaf een boorvloer over de zijde, wat problemen gaf met de slagzij. Hierop werd de CUSS I gebouwd, die boorde door een moonpool in de midscheeps. De CUSS I kon op ankers boren in waterdieptes tot ruim 100 meter.
De CUSS I werd overgenomen door Global Marine, die ook een serie grotere boorschepen liet bouwen. Bij grotere waterdieptes werd ankeren problematisch, en daarom maakte de CUSS I in 1961 tijdens Project Mohole een poging om door de aardkorst te boren in de Mohorovii-discontinuteit gebruik van schroeven om op positie te blijven bij een waterdiepte van zo’n 3500 meter, het begin van dynamic positioning. Desondanks maken nog veel boorschepen en semi-submersibles gebruik van ankersystemen, die lichter zijn geworden door over te stappen van kettingankers naar draadankers en zo bruikbaar zijn tot zeker 1500 meter en met vooraf geplaatste ankers tot nog minstens 1000 meter dieper.
De ontwikkelingen op de Noordzee begonnen pas later, mede door de zwaardere weersomstandigheden, maar vooral omdat gedacht was dat er niet voldoende olie en gas te winnen zou zijn. Daarnaast ontbrak internationale regelgeving over de verdeling van het continentaal plat. In 1958 werd het UNCLOS I verdrag (tegenwoordig onderdeel van het VN Zeerechtverdrag) afgesloten. In 1964 trad het in werking, zodat het continentaal plat van de Noordzee verdeeld werd tussen de aangrenzende landen. Op 29 mei 1959 werd in Kolham de Slochterse gasbel ontdekt, waarmee het vermoeden rees dat ook in de Noordzee aardgas zou zijn te vinden. Op 17 september 1965 boorde het hefeiland Sea Gem gas aan in de BP-concessie, om slechts enkele dagen later te kapseizen. De zware weersomstandigheden vereisten een aanpassing van de gebruikte technologie om veilig te kunnen werken.
Op 6 oktober 1973 brak de Jom Kipoeroorlog uit, waarna de OPEC een olie-embargo instelde voor de Verenigde Staten en Nederland, wat leidde tot de oliecrisis van 1973. Dit bleek een enorme stimulans voor de offshore-sector, vooral op de Noordzee.
Tegenwoordig is de offshore-industrie wereldwijd bezig met de exploratie en winning van olie en gas. Daarbij worden de Golf van Mexico, Brazili en West-Afrika wel gezien als de gouden driehoek, waarbij steeds meer de nadruk komt te liggen op diepwater ( 300 tot 2400 meter) en ultra-diepwater (meer dan 2400 meter).
De ontwikkeling van een olieveld bestaat uit meerdere onderdelen, waarvan het platform de meest zichtbare is, hoewel er ook velden zijn die geheel uit onderzeese installaties bestaan, zoals Ormen Lange. Daarnaast heeft een veld een infrastructuur, zoals olie- en gaspijpleidingen, waterinjectieleidingen, elektriciteitsleidingen en onderzeese installaties die aangelegd moeten worden. De constructie van platforms gebeurt grotendeels op werven aan de wal. De manier waarop deze daarna genstalleerd worden is onder andere afhankelijk van de grootte en de waterdiepte.
Met behulp van lanceerbakken kunnen jackets en compliant towers worden gelanceerd. Om kosten te reduceren nadat in 1986 de olieprijs was gedaald, werden jackets ontworpen die met een kraanschip konden worden genstalleerd. Omdat deze jackets niet ontworpen hoeven te worden voor de krachten die tijdens het lanceren optreden, kunnen deze lichter uitgevoerd worden dan gelanceerde jackets. Zwaardere jackets en compliant towers worden echter nog steeds gelanceerd.
Om op zee te hijsen, kan gebruik worden gemaakt van meerdere opties. Drijvende bokken werden al vroeg gebruikt. De komst van grote kraanschepen maakte constructie goedkoper.
De grootste kraanschepen worden gebruikt voor constructiewerkzaamheden in de offshore. De grotere schepen zijn vaak half-afzinkbaar, maar ook conventionele scheepsvormen (monohulls) worden gebruikt. Het verschil met een drijvende bok is dat de kranen kunnen roteren.
In 1949 liet J. Ray McDermott de Derrick Barge Four bouwen, een bak die uitgerust was met een 150 ton roterende kraan. Met het verschijnen van dit soort schepen veranderde de offshoreconstructie. In plaats van constructie in delen, kunnen jackets en dekken als modules aan de wal worden gebouwd. Voor gebruik in het ondiepe deel van de Golf van Mexico voldeden deze bakken voorlopig.
In 1963 liet Heerema een Noorse tanker, de Sunnaas, ombouwen tot het eerste kraanschip met een capaciteit van 300 ton in de offshore dat een echte scheepsvorm had, waarna het werd omgedoopt tot de Global Adventurer. Dit type kraanschip was beter geschikt voor de weersomstandigheden op de Noordzee.
Het in 1967 opgerichte Netherlands Offshore Company bracht in 1978 het eerste half-afzinkbaar kraanschip in de vaart, de Narwhal. Vanwege financile problemen werden de schepen van NOC verkocht aan McDermott, waarmee het bedrijf ophield te bestaan.
In datzelfde jaar liet Heerema ook twee half-afzinkbare kraanschepen bouwen, de Hermod en de Balder, elk met n 2000 shortton en n 3000 shortton kraan. Later hebben beide overigens een upgrade gekregen, zodat ze nu een grotere capaciteit hebben. Dit type kraanschip was veel minder gevoelig voor zeegang en deining, waardoor ook gedurende de wintermaanden kon worden gewerkt op de Noordzee. De grote stabiliteit laat ook toe dat er zwaarder getild kan worden dan met een monohull. De grotere werkbaarheid en capaciteit van de kranen bracht de installatietijd van een platform terug van een heel seizoen naar een paar weken. Waar de topside van een platform daarvoor opgebouwd moest worden uit vele kleine delen, kon deze nu veelal in een keer geplaatst worden, waardoor de totale constructie lichter uitgevoerd kon worden en een groter deel van het werk aan de wal plaats kon vinden en dus goedkoper was.
Genspireerd door dit succes werden gelijksoortige schepen gebouwd. In 1985 kwam de DB-102 in de vaart voor McDermott, met 2 kranen met een capaciteit van 6000 ton elk. Micoperi liet de M7000 bouwen in 1986 met twee kranen van 7000 ton elk.
Midden jaren tachtig was de hausse in de offshore echter over. De prijs van een vat olie daalde tot onder de $10 waardoor investeringen vrijwel tot stilstand kwamen en samenwerking gezocht moest worden. In 1988 werd een joint venture tussen Heerema en McDermott gevormd, HeereMac. In 1990 moest Micoperi een faillissement aanvragen. Dat gaf Saipem in het begin van de jaren zeventig nog een grote speler in de offshoreconstructie, maar eind jaren tachtig nog maar marginaal aanwezig de kans om in 1995 de M7000 over te nemen. In 1997 nam Heerema de DB-102 over van McDermott na beindiging van de joint venture. Het schip werd omgedoopt in Thialf en na een upgrade in 2000 tot tweemaal 7100 ton is het het grootste kraanschip ter wereld.
Voor dekken met gewichten die kraanschepen niet aankunnen of wanneer deze niet beschikbaar zijn, wordt gebruikgemaakt van bakken voor float-overs. Het gaat hierbij over gewichten van enkele tienduizenden tonnen. De bak wordt hierbij tussen de poten van het jacket gebracht en daarna geballast totdat het overhangende dek op het jacket staat.
Gravity based structures worden met behulp van sleepboten naar locatie gebracht, waarna ze geballast worden tot ze op de zeebodem rusten. Deze techniek is vooral veel gebruikt in Noorwegen, waar veel platforms van het condeeptype staan. Ook drijvende platforms als FPSO’s, TLP’s, semi-submersibles en spars worden naar locatie gesleept om daar vervolgens afgemeerd te worden.
De infrastructuur van een veld bestaat naast een of meerdere platforms uit olie- en gaspijpleidingen, waterinjectieleidingen, elektriciteitsleidingen en onderzeese installaties.
Hoewel ook de kleinere leidingen en installaties door de grote pijpenleggers en kraanschepen worden aangelegd, wordt dit vaak gedaan door zogenaamde Offshore Support Vessels. Deze zijn uitgerust met een kraan die vaak enkele tientallen tot honderden tonnen kan tillen, dan wel met een A-frame waarmee installaties op de zeebodem kunnen worden uitgevoerd.
In ondiep water wordt in de Verenigde Staten ook gebruikgemaakt van liftboten, bootjes met eigen voortstuwing die zich kunnen opheffen zoals een hefeiland en meestal uitgerust zijn met een kraan.
Bij onderzeese pijpleidingen voor een platform wordt onderscheid gemaakt tussen de leidingen waarmee de olie en gas uit diverse putten naar het platform wordt getransporteerd de tie-backs en die waarmee het na behandeling naar de wal wordt getransporteerd de exportleidingen. Export kan ook met behulp van een shuttletanker, maar vindt vaak plaats met behulp van een pijpleiding. Deze worden gelegd met behulp van bakken waarvan de ankers continu verplaatst worden door ankerbehandelingssleepboten. Tegenwoordig zijn de grootste pijpenleggers schepen en voorzien van dynamic positioning. Er zijn verschillende methoden om pijp te leggen. Bij S-lay verlaat de leiding het schip horizontaal, bij J-lay verticaal. Bij reel-lay wordt de pijp gelegd vanaf een grote spoel.
Waar hefeilanden en boorschepen vooral gebruikt worden voor proefboringen en om de uiteindelijke putten te boren, kunnen deze na voltooiing daarvan vertrekken. Na installatie van een productieplatform die vaak booreilanden worden genoemd, hoewel de meeste niet kunnen boren wordt de winning daarmee voortgezet. De beweging naar steeds dieper water heeft een scala aan platforms opgeleverd. Bij grotere waterdieptes werden de normale jackets te groot en zwaar om economisch nog haalbaar te zijn. Waar deze jackets stijf zijn ontworpen om alle weersomstandigheden te kunnen weerstaan, werd voor grotere waterdieptes overgestapt op buigzame constructies, compliant towers die meegeven en daardoor lichter gebouwd kunnen worden. Voor nog grotere waterdieptes ging men over naar drijvende platforms:
In de Verenigde Staten moet van de MMS een platform binnen een jaar na het buiten gebruik stellen worden verwijderd, tenzij gebruik wordt gemaakt van het alternatief volgens de Rigs-to-Reefs-wetgeving. In Europa was het dumpen van afval vanaf schepen en vliegtuigen aan banden gelegd door de Oslo-conventie van 1972, die later is vervangen door het OSPAR-verdrag. De Brent Spar-affaire zorgde voor een aanscherping van dit verdrag in 1998, zodat alle platforms in de Noordzee ontmanteld moeten worden, hoewel dit verdrag meer ruimte laat dan het Verdrag van Helsinki dat geldt voor de Oostzee. Een poging in 1996 om via het Verdrag van Londen het dumpen wereldwijd te verbieden mislukte.
Dit betekent dat er een ontmantelingsmarkt is van enkele honderden platforms op de Noordzee, hoewel deze markt riskanter is dan installatie. Aangezien er geen first oil is aan het einde van het project, is het al snel financieel aantrekkelijk voor een oliemaatschappij om investeringen naar achteren te verschuiven. Een aantal methodes en voorstellen voor ontmanteling zijn gebaseerd op het gebruik van dezelfde kraanschepen die ook voor installatie werden gebruikt.
Andere voorstellen baseren zich vooral op het catamaran-idee, waarbij tussen de twee rompen ruimte is uitgespaard. Deze U-vorm kan dan om een dek of jacket geplaatst worden, waarna ontballast wordt waarmee de constructie gelicht wordt. Andere voorstellen maken gebruik van hydraulische systemen en hijsdraden, eventueel gecombineerd. Voorbeelden zijn Versatruss, de Pieter Schelte van Allseas, de MPU Heavy Lifter van het inmiddels failliete MPU Offshore Lift en de Twin Marine Lifter. Hiervan bestaat alleen de eerste. De Pieter Schelte is nog in de ontwerpfase, de MPU Heavy Lifter wordt gesloopt voordat deze is voltooid en de Twin Marine Lifter is nog in de conceptfase.
Maritieme techniek houdt zich bezig met scheepsbouw en scheepvaart en richt zich ook op het transport van goederen en personen. Offshore is een vakgebied dat zich uit civiele techniek (de constructies), werktuigbouwkunde en scheepsbouwkunde heeft ontwikkeld. De laatste tijd verschuift het vakgebied meer naar de scheepsbouwkundige kant. Dit omdat offshore olie- en gasvelden zich op steeds grotere diepten bevinden. Hiermee komt de switch van ‘fixed platforms’ naar ‘floating platforms’; de laatste zijn vooral een scheepsbouwkundige aangelegenheid.
See the article here:
Posted: October 31, 2016 at 2:52 am
Trance is a genre of electronic dance music that developed during the 1990s in Germany. It is characterized by a tempo lying between 125 and 150 beats per minute (BPM), repeating melodic phrases, and a musical form that distinctly builds tension and elements throughout a track often culminating in 1 to 2 “peaks” or “drops.” Although trance is a genre of its own, it liberally incorporates influences from other musical styles such as techno,house,pop,chill-out,classical music,tech house, ambient, and film music.
A trance refers to a state of hypnotism and heightened consciousness. This is portrayed in trance music by the mixing of layers with distinctly foreshadowed build-up and release. A characteristic of virtually all trance music is a mid-song climax followed by a soft breakdown disposing of beats and percussion entirely, and leaving the melody and/or atmospherics to stand alone for an extended period before gradually building up again. As a result, trance tracks are often lengthy to allow for this progression and have sufficiently sparse opening and closing sections to facilitate mixing by DJs.
Trance can be purely instrumental, although vocals are also a common feature. Typically they are performed by mezzo-soprano to soprano female soloists, often without verse/chorus structure. Structured vocal form in trance music forms the basis of the vocal trance subgenre, which has been described as “grand, soaring, and operatic” and “ethereal female leads floating amongst the synths”.
The trance name may refer to an induced emotional feeling, high, euphoria, chills, or uplifting rush that listeners claim to experience, or it may indicate an actual trance-like state the earliest forms of this music attempted to emulate in the 1990s before the genre’s focus changed.
Some trace Trance’s antecedents back to Klaus Schulze, a German experimental electronic music artist who concentrated in mixing minimalist music repetitive rhythms and arpeggiated sounds (specifically his 1988 album “En=Trance”. In truth it was really Sven Vth, his labels and others in the same group that saw the initial releases of trance Another possible antecedent is Yuzo Koshiro and Motohiro Kawashima’s electronic soundtracks for the Streets of Rage series of video games from 1991 to 1994, and the Wangan Midnight Maximum Tune series. It was promoted by the well-known UK club-night megatripolis (London, Heaven, Thursdays) whose scene catapulted it to international fame.
Examples of early Trance releases include but are not limited to German duo Jam & Spoon’s 1992 12″ Single remix of the 1990 song The Age Of Love., German duo Dance 2 Trance’s 1990 track “We Came in Peace”.
One writer[who?] traces the roots of trance to Paul van Dyk’s 1993 remix of Humate’s “Love Stimulation”. However, van Dyk’s trance origins can be traced further back to his work with Visions Of Shiva, which were his first ever tracks to be released.[original research?] In subsequent years, one genre, vocal trance, arose as the combination of progressive elements and pop music, and the development of another subgenre, epic trance, had some of its origins in classical music., with film music also being influential.
Trance was arguably at its commercial peak in the second part of 1990s and early 2000s.
Classic trance employs a 4/4 time signature, a tempo of 125 to 150 BPM, and 32 beat phrases and is somewhat faster than house music. A kick drum is usually placed on every downbeat and a regular open hi-hat is often placed on the upbeat or every 1/8th division of the bar. Extra percussive elements are usually added, and major transitions, builds or climaxes are often foreshadowed by lengthy “snare rolls”a quick succession of snare drum hits that build in velocity, frequency, and volume towards the end of a measure or phrase.
Rapid arpeggios and minor keys are common features of Trance, the latter being almost universal. Trance tracks often use one central “hook”, or melody, which runs through almost the entire song, repeating at intervals anywhere between 2 beats and 32 bars, in addition to harmonies and motifs in different timbres from the central melody. Instruments are added or removed every 4, 8, 16, or 32 bars.
In the section before the breakdown, the lead motif is often introduced in a sliced up and simplified form, to give the audience a “taste” of what they will hear after the breakdown. Then later, the final climax is usually “a culmination of the first part of the track mixed with the main melodic reprise”.
As is the case with many dance music tracks, trance tracks are usually built with sparser intros (“mix-ins”) and outros (“mix-outs”) in order to enable DJs to blend them together immediately. As trance is more melodic and harmonic than other electronic dance music, the construction of trance tracks in the proper way is particularly important in order to avoid dissonant (or “key clashing,” i.e., out of tune with one another) mixes.
More recent forms of trance music incorporate other styles and elements of electronic music such as electro and progressive house into its production. It emphasizes harsher basslines and drum beats which decrease the importance of offbeats and focus primarily on a four on the floor stylistic house drum pattern. The bpm of more recent styles tends to be on par with house music at 120 – 135 beats per minute. However, unlike house music, recent forms of trance stay true to their melodic breakdowns and longer transitions.
Trance music is broken into a large number of subgenres. Chronologically, the major subgenres are classic trance, acid trance, progressive trance,uplifting trance, and hard trance.Uplifting trance is also known as “anthem trance”, “epic trance”, “commercial trance”, “stadium trance”, or “euphoric trance”, and has been strongly influenced by classical music in the 1990s and 2000s by leading artists such as Ferry Corsten, Armin Van Buuren, Tiesto, Push, Rank 1 and at present with the development of the subgenre “orchestral uplifting trance” or “uplifting trance with symphonic orchestra” by such artists as Andy Blueman, Ciro Visone, Soundlift, Arctic Moon, Sergey Nevone&Simon O’Shine etc. Closely related to Uplifting Trance is Euro-trance, which has become a general term for a wide variety of highly commercialized European dance music. Several subgenres are crossovers with other major genres of electronic music. For instance, Tech trance is a mixture of trance and techno, and Vocal trance “combines [trance’s] progressive elements with pop music”.Balearic beat, which is associated with the laid back vacation lifestyle of Ibiza, Spain, is often called “Balearic trance”, as espoused by Roger Shah. The dream trance genre originated in the mid-1990s, with its popularity then led by Robert Miles. There is also a slower bpm trance music, this styles are often called “psybient” (synonyms are “psychill”, “ambient trance”).
AllMusic states on progressive trance: “the progressive wing of the trance crowd led directly to a more commercial, chart-oriented sound, since trance had never enjoyed much chart action in the first place. Emphasizing the smoother sound of Eurodance or house (and occasionally more reminiscent of Jean-Michel Jarre than Basement Jaxx), Progressive Trance became the sound of the world’s dance floors by the end of the millennium. Critics ridiculed its focus on predictable breakdowns and relative lack of skill to beat-mix, but progressive trance was caned by the hottest DJ.”
The following is an incomplete list of dance music festivals that showcase trance music.
Notes:’ Sunburn was not the first festival/event to specialize in India in trance music much earlier pioneers of Goa parties held events as early as the late 80’s and through all of the 1990s
Electronic Dance Music festivals in the Netherlands are mainly organized by four companies ALDA Events, ID&T, UDC and Q-dance:
Electronic music festivals in the US feature various Electronic Dance Music genres such as trance, House, Techno, Electro, Dubstep, and Drum & Bass:
The trance scene in South America is constantly growing. The most important trance festival in South America is called Universo Parallelo.
Posted: October 27, 2016 at 12:08 pm
All fields are required except where indicated. Your Information Address City Country State/Prov Zip/Postal code United States Canada Afghanistan land Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua And Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia And Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, The Democratic Republic Of The Cook Islands Costa Rica Cte D’Ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island And Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic Of Iraq Ireland Isle Of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic Of Korea, Republic Of Kosovo Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic Of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States Of Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Runion Romania Russian Federation Rwanda Saint Barthlemy Saint Helena Saint Kitts And Nevis Saint Lucia Saint Martin Saint Pierre And Miquelon Saint Vincent And The Grenadines Samoa San Marino Sao Tome And Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia And The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard And Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic Of Thailand Timor-leste Togo Tokelau Tonga Trinidad And Tobago Tunisia Turkey Turkmenistan Turks And Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom Uruguay Uzbekistan Vanuatu Vatican City State Venezuela Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis And Futuna Western Sahara Yemen Zambia Zimbabwe Your grade level 12College Major Your Teacher and School Information Name of school Address City Country State/Prov Zip/Postal code United States Canada Afghanistan land Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua And Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia And Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, The Democratic Republic Of The Cook Islands Costa Rica Cte D’Ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island And Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic Of Iraq Ireland Isle Of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic Of Korea, Republic Of Kosovo Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic Of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States Of Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Runion Romania Russian Federation Rwanda Saint Barthlemy Saint Helena Saint Kitts And Nevis Saint Lucia Saint Martin Saint Pierre And Miquelon Saint Vincent And The Grenadines Samoa San Marino Sao Tome And Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia And The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard And Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic Of Thailand Timor-leste Togo Tokelau Tonga Trinidad And Tobago Tunisia Turkey Turkmenistan Turks And Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom Uruguay Uzbekistan Vanuatu Vatican City State Venezuela Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis And Futuna Western Sahara Yemen Zambia Zimbabwe Name of the teacher who assigned the essay (if applicable) Your Essay Please select the topic question your essay addresses Topic 1: Francisco d’Anconia says that the “words ‘to make money’ Topic 2: Atlas Shrugged is both a celebration of business and a defense Topic 3: Ragnar Danneskjld says he loves that which has rarely been loved,
Francisco d’Anconia says that the “words ‘to make money’ hold the essence of human morality.” What does he mean? What are today’s prevalent moral attitudes toward money? Do you agree with Franciscos view? Explain why or why not.
Atlas Shrugged is both a celebration of business and a defense of it against widespread attacks. Judging from the novel, as well as from Ayn Rand’s essay “What Is Capitalism?” and her speech “America’s Persecuted Minority: Big Business,” why does she think business should be defended and championed? What does she think is a proper defense of business, and why?
Ragnar Danneskjld says he loves that which has rarely been loved, namely, human ability. What do you think this means? How does it relate to the idea: “From each according to his ability, to each according to his need”? Do you agree or disagree with Ragnar’s attitude? Explain.
Have you checked to ensure that all personally identifiable information has been removed from your essay?
Continue reading here:
Posted: October 25, 2016 at 7:36 am
Gene therapy is the therapeutic delivery of nucleic acid polymers into a patient’s cells as a drug to treat disease. The first attempt at modifying human DNA was performed in 1980 by Martin Cline, but the first successful and approved[by whom?] nuclear gene transfer in humans was performed in May 1989. The first therapeutic use of gene transfer as well as the first direct insertion of human DNA into the nuclear genome was performed by French Anderson in a trial starting in September 1990.
Between 1989 and February 2016, over 2,300 clinical trials had been conducted, more than half of them in phase I.
It should be noted that not all medical procedures that introduce alterations to a patient’s genetic makeup can be considered gene therapy. Bone marrow transplantation and organ transplants in general have been found to introduce foreign DNA into patients. Gene therapy is defined by the precision of the procedure and the intention of direct therapeutic effects.
Gene therapy was conceptualized in 1972, by authors who urged caution before commencing human gene therapy studies.
The first attempt, an unsuccessful one, at gene therapy (as well as the first case of medical transfer of foreign genes into humans not counting organ transplantation) was performed by Martin Cline on 10 July 1980. Cline claimed that one of the genes in his patients was active six months later, though he never published this data or had it verified and even if he is correct, it’s unlikely it produced any significant beneficial effects treating beta-thalassemia.
After extensive research on animals throughout the 1980s and a 1989 bacterial gene tagging trial on humans, the first gene therapy widely accepted as a success was demonstrated in a trial that started on September 14, 1990, when Ashi DeSilva was treated for ADA-SCID.
The first somatic treatment that produced a permanent genetic change was performed in 1993.
This procedure was referred to sensationally and somewhat inaccurately in the media as a “three parent baby”, though mtDNA is not the primary human genome and has little effect on an organism’s individual characteristics beyond powering their cells.
Gene therapy is a way to fix a genetic problem at its source. The polymers are either translated into proteins, interfere with target gene expression, or possibly correct genetic mutations.
The most common form uses DNA that encodes a functional, therapeutic gene to replace a mutated gene. The polymer molecule is packaged within a “vector”, which carries the molecule inside cells.
Early clinical failures led to dismissals of gene therapy. Clinical successes since 2006 regained researchers’ attention, although as of 2014, it was still largely an experimental technique. These include treatment of retinal diseases Leber’s congenital amaurosis and choroideremia,X-linked SCID, ADA-SCID,adrenoleukodystrophy,chronic lymphocytic leukemia (CLL),acute lymphocytic leukemia (ALL),multiple myeloma,haemophilia and Parkinson’s disease. Between 2013 and April 2014, US companies invested over $600 million in the field.
The first commercial gene therapy, Gendicine, was approved in China in 2003 for the treatment of certain cancers. In 2011 Neovasculgen was registered in Russia as the first-in-class gene-therapy drug for treatment of peripheral artery disease, including critical limb ischemia. In 2012 Glybera, a treatment for a rare inherited disorder, became the first treatment to be approved for clinical use in either Europe or the United States after its endorsement by the European Commission.
Following early advances in genetic engineering of bacteria, cells, and small animals, scientists started considering how to apply it to medicine. Two main approaches were considered replacing or disrupting defective genes. Scientists focused on diseases caused by single-gene defects, such as cystic fibrosis, haemophilia, muscular dystrophy, thalassemia and sickle cell anemia. Glybera treats one such disease, caused by a defect in lipoprotein lipase.
DNA must be administered, reach the damaged cells, enter the cell and express/disrupt a protein. Multiple delivery techniques have been explored. The initial approach incorporated DNA into an engineered virus to deliver the DNA into a chromosome.Naked DNA approaches have also been explored, especially in the context of vaccine development.
Generally, efforts focused on administering a gene that causes a needed protein to be expressed. More recently, increased understanding of nuclease function has led to more direct DNA editing, using techniques such as zinc finger nucleases and CRISPR. The vector incorporates genes into chromosomes. The expressed nucleases then knock out and replace genes in the chromosome. As of 2014 these approaches involve removing cells from patients, editing a chromosome and returning the transformed cells to patients.
Gene editing is a potential approach to alter the human genome to treat genetic diseases, viral diseases, and cancer. As of 2016 these approaches were still years from being medicine.
Gene therapy may be classified into two types:
In somatic cell gene therapy (SCGT), the therapeutic genes are transferred into any cell other than a gamete, germ cell, gametocyte or undifferentiated stem cell. Any such modifications affect the individual patient only, and are not inherited by offspring. Somatic gene therapy represents mainstream basic and clinical research, in which therapeutic DNA (either integrated in the genome or as an external episome or plasmid) is used to treat disease.
Over 600 clinical trials utilizing SCGT are underway in the US. Most focus on severe genetic disorders, including immunodeficiencies, haemophilia, thalassaemia and cystic fibrosis. Such single gene disorders are good candidates for somatic cell therapy. The complete correction of a genetic disorder or the replacement of multiple genes is not yet possible. Only a few of the trials are in the advanced stages.
In germline gene therapy (GGT), germ cells (sperm or eggs) are modified by the introduction of functional genes into their genomes. Modifying a germ cell causes all the organism’s cells to contain the modified gene. The change is therefore heritable and passed on to later generations. Australia, Canada, Germany, Israel, Switzerland and the Netherlands prohibit GGT for application in human beings, for technical and ethical reasons, including insufficient knowledge about possible risks to future generations and higher risks versus SCGT. The US has no federal controls specifically addressing human genetic modification (beyond FDA regulations for therapies in general).
The delivery of DNA into cells can be accomplished by multiple methods. The two major classes are recombinant viruses (sometimes called biological nanoparticles or viral vectors) and naked DNA or DNA complexes (non-viral methods).
In order to replicate, viruses introduce their genetic material into the host cell, tricking the host’s cellular machinery into using it as blueprints for viral proteins. Scientists exploit this by substituting a virus’s genetic material with therapeutic DNA. (The term ‘DNA’ may be an oversimplification, as some viruses contain RNA, and gene therapy could take this form as well.) A number of viruses have been used for human gene therapy, including retrovirus, adenovirus, lentivirus, herpes simplex, vaccinia and adeno-associated virus. Like the genetic material (DNA or RNA) in viruses, therapeutic DNA can be designed to simply serve as a temporary blueprint that is degraded naturally or (at least theoretically) to enter the host’s genome, becoming a permanent part of the host’s DNA in infected cells.
Non-viral methods present certain advantages over viral methods, such as large scale production and low host immunogenicity. However, non-viral methods initially produced lower levels of transfection and gene expression, and thus lower therapeutic efficacy. Later technology remedied this deficiency.
Methods for non-viral gene therapy include the injection of naked DNA, electroporation, the gene gun, sonoporation, magnetofection, the use of oligonucleotides, lipoplexes, dendrimers, and inorganic nanoparticles.
Some of the unsolved problems include:
Three patients’ deaths have been reported in gene therapy trials, putting the field under close scrutiny. The first was that of Jesse Gelsinger in 1999. One X-SCID patient died of leukemia in 2003. In 2007, a rheumatoid arthritis patient died from an infection; the subsequent investigation concluded that the death was not related to gene therapy.
In 1972 Friedmann and Roblin authored a paper in Science titled “Gene therapy for human genetic disease?” Rogers (1970) was cited for proposing that exogenous good DNA be used to replace the defective DNA in those who suffer from genetic defects.
In 1984 a retrovirus vector system was designed that could efficiently insert foreign genes into mammalian chromosomes.
The first approved gene therapy clinical research in the US took place on 14 September 1990, at the National Institutes of Health (NIH), under the direction of William French Anderson. Four-year-old Ashanti DeSilva received treatment for a genetic defect that left her with ADA-SCID, a severe immune system deficiency. The effects were temporary, but successful.
Cancer gene therapy was introduced in 1992/93 (Trojan et al. 1993). The treatment of glioblastoma multiforme, the malignant brain tumor whose outcome is always fatal, was done using a vector expressing antisense IGF-I RNA (clinical trial approved by NIH n 1602, and FDA in 1994). This therapy also represents the beginning of cancer immunogene therapy, a treatment which proves to be effective due to the anti-tumor mechanism of IGF-I antisense, which is related to strong immune and apoptotic phenomena.
In 1992 Claudio Bordignon, working at the Vita-Salute San Raffaele University, performed the first gene therapy procedure using hematopoietic stem cells as vectors to deliver genes intended to correct hereditary diseases. In 2002 this work led to the publication of the first successful gene therapy treatment for adenosine deaminase-deficiency (SCID). The success of a multi-center trial for treating children with SCID (severe combined immune deficiency or “bubble boy” disease) from 2000 and 2002, was questioned when two of the ten children treated at the trial’s Paris center developed a leukemia-like condition. Clinical trials were halted temporarily in 2002, but resumed after regulatory review of the protocol in the US, the United Kingdom, France, Italy and Germany.
In 1993 Andrew Gobea was born with SCID following prenatal genetic screening. Blood was removed from his mother’s placenta and umbilical cord immediately after birth, to acquire stem cells. The allele that codes for adenosine deaminase (ADA) was obtained and inserted into a retrovirus. Retroviruses and stem cells were mixed, after which the viruses inserted the gene into the stem cell chromosomes. Stem cells containing the working ADA gene were injected into Andrew’s blood. Injections of the ADA enzyme were also given weekly. For four years T cells (white blood cells), produced by stem cells, made ADA enzymes using the ADA gene. After four years more treatment was needed.
Jesse Gelsinger’s death in 1999 impeded gene therapy research in the US. As a result, the FDA suspended several clinical trials pending the reevaluation of ethical and procedural practices.
The modified cancer gene therapy strategy of antisense IGF-I RNA (NIH n 1602) using antisense / triple helix anti IGF-I approach was registered in 2002 by Wiley gene therapy clinical trial – n 635 and 636. The approach has shown promising results in the treatment of six different malignant tumors: glioblastoma, cancers of liver, colon, prostate, uterus and ovary (Collaborative NATO Science Programme on Gene Therapy USA, France, Poland n LST 980517 conducted by J. Trojan) (Trojan et al., 2012). This antigene antisense/triple helix therapy has proven to be efficient, due to the mechanism stopping simultaneously IGF-I expression on translation and transcription levels, strengthening anti-tumor immune and apoptotic phenomena.
Sickle-cell disease can be treated in mice. The mice which have essentially the same defect that causes human cases used a viral vector to induce production of fetal hemoglobin (HbF), which normally ceases to be produced shortly after birth. In humans, the use of hydroxyurea to stimulate the production of HbF temporarily alleviates sickle cell symptoms. The researchers demonstrated this treatment to be a more permanent means to increase therapeutic HbF production.
A new gene therapy approach repaired errors in messenger RNA derived from defective genes. This technique has the potential to treat thalassaemia, cystic fibrosis and some cancers.
Researchers created liposomes 25 nanometers across that can carry therapeutic DNA through pores in the nuclear membrane.
In 2003 a research team inserted genes into the brain for the first time. They used liposomes coated in a polymer called polyethylene glycol, which, unlike viral vectors, are small enough to cross the bloodbrain barrier.
Short pieces of double-stranded RNA (short, interfering RNAs or siRNAs) are used by cells to degrade RNA of a particular sequence. If a siRNA is designed to match the RNA copied from a faulty gene, then the abnormal protein product of that gene will not be produced.
Gendicine is a cancer gene therapy that delivers the tumor suppressor gene p53 using an engineered adenovirus. In 2003, it was approved in China for the treatment of head and neck squamous cell carcinoma.
In March researchers announced the successful use of gene therapy to treat two adult patients for X-linked chronic granulomatous disease, a disease which affects myeloid cells and damages the immune system. The study is the first to show that gene therapy can treat the myeloid system.
In May a team reported a way to prevent the immune system from rejecting a newly delivered gene. Similar to organ transplantation, gene therapy has been plagued by this problem. The immune system normally recognizes the new gene as foreign and rejects the cells carrying it. The research utilized a newly uncovered network of genes regulated by molecules known as microRNAs. This natural function selectively obscured their therapeutic gene in immune system cells and protected it from discovery. Mice infected with the gene containing an immune-cell microRNA target sequence did not reject the gene.
In August scientists successfully treated metastatic melanoma in two patients using killer T cells genetically retargeted to attack the cancer cells.
In November researchers reported on the use of VRX496, a gene-based immunotherapy for the treatment of HIV that uses a lentiviral vector to deliver an antisense gene against the HIV envelope. In a phase I clinical trial, five subjects with chronic HIV infection who had failed to respond to at least two antiretroviral regimens were treated. A single intravenous infusion of autologous CD4 T cells genetically modified with VRX496 was well tolerated. All patients had stable or decreased viral load; four of the five patients had stable or increased CD4 T cell counts. All five patients had stable or increased immune response to HIV antigens and other pathogens. This was the first evaluation of a lentiviral vector administered in a US human clinical trial.
In May researchers announced the first gene therapy trial for inherited retinal disease. The first operation was carried out on a 23-year-old British male, Robert Johnson, in early 2007.
Leber’s congenital amaurosis is an inherited blinding disease caused by mutations in the RPE65 gene. The results of a small clinical trial in children were published in April. Delivery of recombinant adeno-associated virus (AAV) carrying RPE65 yielded positive results. In May two more groups reported positive results in independent clinical trials using gene therapy to treat the condition. In all three clinical trials, patients recovered functional vision without apparent side-effects.
In September researchers were able to give trichromatic vision to squirrel monkeys. In November 2009, researchers halted a fatal genetic disorder called adrenoleukodystrophy in two children using a lentivirus vector to deliver a functioning version of ABCD1, the gene that is mutated in the disorder.
An April paper reported that gene therapy addressed achromatopsia (color blindness) in dogs by targeting cone photoreceptors. Cone function and day vision were restored for at least 33 months in two young specimens. The therapy was less efficient for older dogs.
In September it was announced that an 18-year-old male patient in France with beta-thalassemia major had been successfully treated. Beta-thalassemia major is an inherited blood disease in which beta haemoglobin is missing and patients are dependent on regular lifelong blood transfusions. The technique used a lentiviral vector to transduce the human -globin gene into purified blood and marrow cells obtained from the patient in June 2007. The patient’s haemoglobin levels were stable at 9 to 10 g/dL. About a third of the hemoglobin contained the form introduced by the viral vector and blood transfusions were not needed. Further clinical trials were planned.Bone marrow transplants are the only cure for thalassemia, but 75% of patients do not find a matching donor.
Cancer immunogene therapy using modified anti gene, antisense / triple helix approach was introduced in South America in 2010/11 in La Sabana University, Bogota (Ethical Committee 14.12.2010, no P-004-10). Considering the ethical aspect of gene diagnostic and gene therapy targeting IGF-I, the IGF-I expressing tumors i.e. lung and epidermis cancers, were treated (Trojan et al. 2016). 
In 2007 and 2008, a man was cured of HIV by repeated Hematopoietic stem cell transplantation (see also Allogeneic stem cell transplantation, Allogeneic bone marrow transplantation, Allotransplantation) with double-delta-32 mutation which disables the CCR5 receptor. This cure was accepted by the medical community in 2011. It required complete ablation of existing bone marrow, which is very debilitating.
In August two of three subjects of a pilot study were confirmed to have been cured from chronic lymphocytic leukemia (CLL). The therapy used genetically modified T cells to attack cells that expressed the CD19 protein to fight the disease. In 2013, the researchers announced that 26 of 59 patients had achieved complete remission and the original patient had remained tumor-free.
Human HGF plasmid DNA therapy of cardiomyocytes is being examined as a potential treatment for coronary artery disease as well as treatment for the damage that occurs to the heart after myocardial infarction.
In 2011 Neovasculgen was registered in Russia as the first-in-class gene-therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for VEGF. Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF.
The FDA approved Phase 1 clinical trials on thalassemia major patients in the US for 10 participants in July. The study was expected to continue until 2015.
In July 2012, the European Medicines Agency recommended approval of a gene therapy treatment for the first time in either Europe or the United States. The treatment used Alipogene tiparvovec (Glybera) to compensate for lipoprotein lipase deficiency, which can cause severe pancreatitis. The recommendation was endorsed by the European Commission in November 2012 and commercial rollout began in late 2014.
In December 2012, it was reported that 10 of 13 patients with multiple myeloma were in remission “or very close to it” three months after being injected with a treatment involving genetically engineered T cells to target proteins NY-ESO-1 and LAGE-1, which exist only on cancerous myeloma cells.
In March researchers reported that three of five subjects who had acute lymphocytic leukemia (ALL) had been in remission for five months to two years after being treated with genetically modified T cells which attacked cells with CD19 genes on their surface, i.e. all B-cells, cancerous or not. The researchers believed that the patients’ immune systems would make normal T-cells and B-cells after a couple of months. They were also given bone marrow. One patient relapsed and died and one died of a blood clot unrelated to the disease.
Following encouraging Phase 1 trials, in April, researchers announced they were starting Phase 2 clinical trials (called CUPID2 and SERCA-LVAD) on 250 patients at several hospitals to combat heart disease. The therapy was designed to increase the levels of SERCA2, a protein in heart muscles, improving muscle function. The FDA granted this a Breakthrough Therapy Designation to accelerate the trial and approval process. In 2016 it was reported that no improvement was found from the CUPID 2 trial.
In July researchers reported promising results for six children with two severe hereditary diseases had been treated with a partially deactivated lentivirus to replace a faulty gene and after 732 months. Three of the children had metachromatic leukodystrophy, which causes children to lose cognitive and motor skills. The other children had Wiskott-Aldrich syndrome, which leaves them to open to infection, autoimmune diseases and cancer. Follow up trials with gene therapy on another six children with Wiskott-Aldrich syndrome were also reported as promising.
In October researchers reported that two children born with adenosine deaminase severe combined immunodeficiency disease (ADA-SCID) had been treated with genetically engineered stem cells 18 months previously and that their immune systems were showing signs of full recovery. Another three children were making progress. In 2014 a further 18 children with ADA-SCID were cured by gene therapy. ADA-SCID children have no functioning immune system and are sometimes known as “bubble children.”
Also in October researchers reported that they had treated six haemophilia sufferers in early 2011 using an adeno-associated virus. Over two years later all six were producing clotting factor.
Data from three trials on Topical cystic fibrosis transmembrane conductance regulator gene therapy were reported to not support its clinical use as a mist inhaled into the lungs to treat cystic fibrosis patients with lung infections.
In January researchers reported that six choroideremia patients had been treated with adeno-associated virus with a copy of REP1. Over a six-month to two-year period all had improved their sight. By 2016, 32 patients had been treated with positive results and researchers were hopeful the treatment would be long-lasting. Choroideremia is an inherited genetic eye disease with no approved treatment, leading to loss of sight.
In March researchers reported that 12 HIV patients had been treated since 2009 in a trial with a genetically engineered virus with a rare mutation (CCR5 deficiency) known to protect against HIV with promising results.
Clinical trials of gene therapy for sickle cell disease were started in 2014 although one review failed to find any such trials.
In February LentiGlobin BB305, a gene therapy treatment undergoing clinical trials for treatment of beta thalassemia gained FDA “breakthrough” status after several patients were able to forgo the frequent blood transfusions usually required to treat the disease.
In March researchers delivered a recombinant gene encoding a broadly neutralizing antibody into monkeys infected with simian HIV; the monkeys’ cells produced the antibody, which cleared them of HIV. The technique is named immunoprophylaxis by gene transfer (IGT). Animal tests for antibodies to ebola, malaria, influenza and hepatitis are underway.
In March scientists, including an inventor of CRISPR, urged a worldwide moratorium on germline gene therapy, writing scientists should avoid even attempting, in lax jurisdictions, germline genome modification for clinical application in humans until the full implications are discussed among scientific and governmental organizations.
Also in 2015 Glybera was approved for the German market.
In October, researchers announced that they had treated a baby girl, Layla Richards, with an experimental treatment using donor T-cells genetically engineered to attack cancer cells. Two months after the treatment she was still free of her cancer (a highly aggressive form of acute lymphoblastic leukaemia [ALL]). Children with highly aggressive ALL normally have a very poor prognosis and Layla’s disease had been regarded as terminal before the treatment.
In December, scientists of major world academies called for a moratorium on inheritable human genome edits, including those related to CRISPR-Cas9 technologies but that basic research including embryo gene editing should continue.
In April the Committee for Medicinal Products for Human Use of the European Medicines Agency endorsed a gene therapy treatment called Strimvelis and recommended it be approved. This treats children born with ADA-SCID and who have no functioning immune system – sometimes called the “bubble baby” disease. This would be the second gene therapy treatment to be approved in Europe.
Speculated uses for gene therapy include:
Gene Therapy techniques have the potential to provide alternative treatments for those with infertility. Recently, successful experimentation on mice has proven that fertility can be restored by using the gene therapy method, CRISPR. Spermatogenical stem cells from another organism were transplanted into the testes of an infertile male mouse. The stem cells re-established spermatogenesis and fertility.
Athletes might adopt gene therapy technologies to improve their performance.Gene doping is not known to occur, but multiple gene therapies may have such effects. Kayser et al. argue that gene doping could level the playing field if all athletes receive equal access. Critics claim that any therapeutic intervention for non-therapeutic/enhancement purposes compromises the ethical foundations of medicine and sports.
Genetic engineering could be used to change physical appearance, metabolism, and even improve physical capabilities and mental faculties such as memory and intelligence. Ethical claims about germline engineering include beliefs that every fetus has a right to remain genetically unmodified, that parents hold the right to genetically modify their offspring, and that every child has the right to be born free of preventable diseases. For adults, genetic engineering could be seen as another enhancement technique to add to diet, exercise, education, cosmetics and plastic surgery. Another theorist claims that moral concerns limit but do not prohibit germline engineering.
Possible regulatory schemes include a complete ban, provision to everyone, or professional self-regulation. The American Medical Associations Council on Ethical and Judicial Affairs stated that “genetic interventions to enhance traits should be considered permissible only in severely restricted situations: (1) clear and meaningful benefits to the fetus or child; (2) no trade-off with other characteristics or traits; and (3) equal access to the genetic technology, irrespective of income or other socioeconomic characteristics.”
As early in the history of biotechnology as 1990, there have been scientists opposed to attempts to modify the human germline using these new tools, and such concerns have continued as technology progressed. With the advent of new techniques like CRISPR, in March 2015 a group of scientists urged a worldwide moratorium on clinical use of gene editing technologies to edit the human genome in a way that can be inherited. In April 2015, researchers sparked controversy when they reported results of basic research to edit the DNA of non-viable human embryos using CRISPR.
Regulations covering genetic modification are part of general guidelines about human-involved biomedical research.
The Helsinki Declaration (Ethical Principles for Medical Research Involving Human Subjects) was amended by the World Medical Association’s General Assembly in 2008. This document provides principles physicians and researchers must consider when involving humans as research subjects. The Statement on Gene Therapy Research initiated by the Human Genome Organization (HUGO) in 2001 provides a legal baseline for all countries. HUGOs document emphasizes human freedom and adherence to human rights, and offers recommendations for somatic gene therapy, including the importance of recognizing public concerns about such research.
No federal legislation lays out protocols or restrictions about human genetic engineering. This subject is governed by overlapping regulations from local and federal agencies, including the Department of Health and Human Services, the FDA and NIH’s Recombinant DNA Advisory Committee. Researchers seeking federal funds for an investigational new drug application, (commonly the case for somatic human genetic engineering), must obey international and federal guidelines for the protection of human subjects.
NIH serves as the main gene therapy regulator for federally funded research. Privately funded research is advised to follow these regulations. NIH provides funding for research that develops or enhances genetic engineering techniques and to evaluate the ethics and quality in current research. The NIH maintains a mandatory registry of human genetic engineering research protocols that includes all federally funded projects.
An NIH advisory committee published a set of guidelines on gene manipulation. The guidelines discuss lab safety as well as human test subjects and various experimental types that involve genetic changes. Several sections specifically pertain to human genetic engineering, including Section III-C-1. This section describes required review processes and other aspects when seeking approval to begin clinical research involving genetic transfer into a human patient. The protocol for a gene therapy clinical trial must be approved by the NIH’s Recombinant DNA Advisory Committee prior to any clinical trial beginning; this is different from any other kind of clinical trial.
As with other kinds of drugs, the FDA regulates the quality and safety of gene therapy products and supervises how these products are used clinically. Therapeutic alteration of the human genome falls under the same regulatory requirements as any other medical treatment. Research involving human subjects, such as clinical trials, must be reviewed and approved by the FDA and an Institutional Review Board.
Gene therapy is the basis for the plotline of the film I Am Legend and the TV show Will Gene Therapy Change the Human Race?.
Gene therapy – Wikipedia
Posted: at 7:35 am
This article is about the one-way manned trip to Mars proposed for 2026. For the first Soviet spacecraft for Mars, see Mars 1. For other uses, see Mars 1 (disambiguation).
Mars One is an organization based in the Netherlands that has proposed to land the first humans on Mars and establish a permanent human colony there by 2026. The private spaceflight project is led by Dutch entrepreneur Bas Lansdorp, who announced the Mars One project in May 2012. The project’s schedule, technical and financial feasibility, and ethics, have been criticized by scientists, engineers and those in the aerospace industry.
Mars One’s original concept included launching a robotic lander and orbiter as early as 2016 to be followed by a human crew of four in 2022. Organizers plan for the crew to be selected from applicants who paid an administrative fee, to become the first permanent residents of Mars with no plan of returning to Earth. Partial funding options, which have yet to be realized, include a proposed reality television program documenting the journey. In February 2015, the primary contractors on the initial pre-Phase A contracts had completed all studies paid for by Mars One at that time. The current state of the Mission Plan Deliverables (either in the form of Studies or actual Hardware) will be tracked in Table 2 in the Technology section.
The Mars One organization is the controlling stockholder of the for-profit Interplanetary Media Group.
The concept for Mars One began in 2011 with discussions between the two founders, Bas Lansdorp and Arno Wielders.
The Mars One project has no connection with Inspiration Mars, a similarly-timed project to send a married couple on a Mars flyby and return them to Earth over a period of 500 days.
Mars One publicly announced the concept in May 2012 for a one-way trip to Mars, with the intention of an initial robotic precursor mission in 2020 and transporting the first human colonists to Mars in 2024. In a 2015 debate, Bas Lansdrop clarified that “were not going to do, I think, the current design of the mission” and “Mars One’s goal is not to send humans to Mars in 2027 with a $6 billion budget and 14 launches. Our goal is to send humans to Mars, period.” According to Mars One’s website, “It is Mars One’s goal to establish a permanent human settlement on Mars.”
In December 2013, Mars One announced its concept of a robotic precursor mission in 2018, two years later than had been conceptually planned in the 2012 announcements. The robotic lander would be “built by Lockheed Martin based on the design used for NASA’s Phoenix and InSight missions, as well as a communications orbiter built by Surrey Satellite Technology Ltd.” In February 2015, Lockheed Martin and Surrey Satellite Technology confirmed that contracts on the initial study phase begun in late 2013 had run out and additional contracts had not been received for further progress on the robotic missions. Plans have been disclosed to raise the US$200 million or more needed to support the initial robotic mission, but some critics do not find the economic plans to raise money from private investors and exclusive broadcasting rights to be sufficient to support the initial, or follow-on, mission(s).
Mars One selected a second-round pool of astronaut candidates in 2013 of 1058 people”586 men and 472 women from 107 countries”from a larger number of 202,586 who initially showed interest on the Mars One website, although this number is heavily disputed. Former Mars One candidate Dr. Joseph Roche claims the number of initial applicants was only 2,761, which Mars One later conceded via YouTube video.
Mars One announced a partnership with Uwingu on 3 March 2014, stating that the program would use Uwingu’s map of Mars in all of their planned missions.Kristian von Bengtson began work on Simulation Mars Home for crew on 24 March 2014.
The second-round pool was whittled down to 705 candidates (418 men and 287 women) in the beginning of May 2014. 353 were removed due to personal considerations. After the medical physical requirement, which was similar to a normal FAA exam plus EKG, due either to financial, health or access reasons, only 660 candidates remained. Notably, some applicants were notified of life-threatening conditions such as early-stage cancer and were able to immediately begin treatment. These selected persons will then begin the interview process following which several teams of two men and two women will be compiled. The teams will then begin training full-time for a potential future mission to Mars, while individuals and teams may be selected out during training if they are not deemed suitable for the mission.
On June 2, 2014, Darlow Smithson Productions (DSP) announced it has gained exclusive access to Mars One.
On June 30, 2014, it was made public that Mars One seeks financial investment through a bidding process to send company experiments to Mars. The experiment slots will go to the highest bidder and will include company-related ads, and the opportunity to have the company name on the robotic lander that is proposed to carry the experiments to Mars in 2018.
Mars One selected a third-round pool of astronaut candidates in 2015 of 100 people “50 men and 50 women who successfully passed the second round. The candidates come from all around the world, namely 39 from the Americas, 31 from Europe, 16 from Asia, 7 from Africa, and 7 from Oceania”.
In a video posted on 19 of March 2015, Lansdorp said that because of delays in the robotic precursor mission, the first crew will not set down on Mars until 2027. In August 2015, Lansdorp reiterated that their 12-year plan for landing humans on Mars by 2027 is subject to constant improvement and updates.
The Space Review reported in October 2016 that while Mars One was “successful in generating a tremendous amount of publicity as well as enormous excitement about Mars, … its proposal lacked substance both in mission architecture and in workable funding mechanisms. As such, it has faded from the public consciousness.”
According to their schedule as of March 2015, the first crew of four astronauts would arrive on Mars in 2027, after a seven-month journey from Earth. Additional teams would join the settlement every two years, with the intention that by 2035 there would be over twenty people living and working on Mars. The astronaut selection process began on 22 April 2013.
As of July 2015[update], the fourth round astronaut selection process, planned for Sept 2016, by which Mars One will choose six teams of four out of the 100 people selected in the third round, was announced.
In December 2013, mission concept studies for an unmanned Mars mission were contracted with Lockheed Martin and Surrey Satellite Technology for a demonstration mission to be launched in 2017 and land on Mars in 2018. It would be based on the design of the successful 2007 NASA Phoenix lander, and provide proof of concept for a subset of the key technologies for a later permanent human settlement on Mars. Upon submission of Lockheed Martin’s Proposal Information Package, Mars One released a Request for Proposals for the various payloads on the lander. The total payload mass of 44kg is divided among the seven payloads as follows:
In 2022, an unmanned rover will be launched to Mars in order to pick a landing site for the 2027 Mars One landing and a site for the Mars One colony. At the same time, a communication satellite will be launched, enabling continuous communication with the Mars One colony.
In 2024, the 6 cargo missions will be launched in close succession, consisting of two living units, two life-support units, and two supply units.
A spacecraft containing four astronauts will be launched from Earth to meet a Transit vehicle bound for Mars.
In 2027, the landing module will land on Mars, containing four astronauts. They will be met by the rover launched in 2020, and taken to the Mars One colony.
The application was available from 22 April 2013 to 31 August 2013. This first application consists of applicants general information, a motivational letter, a rsum and a video. More than 200,000 people expressed interest, so Mars One plans to hold several other application periods in the future.
By 9 September 2013, 4,227 applicants had paid their registration fee and submitted public videos in which they made their case for going to Mars in 2023. The application fee varies from US $5 to US $75 (the amount depending on the relative wealth of the applicant’s country).
Distribution of the 1,058 applicants selected for Round 2 according to the academic degree
The results of applicants selected for round 2 were declared on 30 December 2013. A total of 1,058 applicants from 107 countries were selected. The gender split is 586 male (55.4%) and 472 female (44.6%). Among the people that were selected for round 2, 159 have a master’s degree, 347 have bachelor’s degrees and 29 have Doctor of Medicine (M.D.) degrees. The majority of the applicants are under 36 and well educated.
Medically cleared candidates were interviewed, and 50 men and 50 women from the total pool of 660 from around the world were selected to move on to the third round of the astronaut selection process:
Although initial plans were for the Mars One selection committee to perform regional interviews around the world, applicants were ultimately remotely interviewed and recorded by Mars One over a relatively short Skype/SparkHire call regarding Martian-related orbital, temp/pressure, geological and historical parameters and the specific elements of the Mars One one-way mission. Dr. Joseph Roche, one of the finalists, has accused the selection process of being based on a point system that is primarily dependent on how much money each individual generated or gave to the Mars One organization, despite many of the round three selectees having not spent any money in the process, apart from the application fee, which varied as a function of each applicant’s country GDP. Lansdorp acknowledges a “gamification” point system but denies that selection is based on money earned. Roche also stated that if paid for interviews, they are asked to donate 75% of the payment to Mars One. This was confirmed by Lansdorp.
It was originally planned that the pool of roughly one thousand successful applicants would be narrowed through regional contests. These events did not take place, and the above-mentioned group of 100 candidates were selected through the remote interview process and selected directly to round 3 in February 2015.
In late 2013, details of the 2015 selection phases had not been agreed upon due to ongoing negotiations with media companies for the rights to televise the selection processes.[needs update]
It was planned that the regional selection may be broadcast on TV and Internet in countries around the world. In each region, plans included 2040 applicants participating in challenges including rigorous simulations, many in team settings, with focus on testing the physical and emotional capabilities of the remaining candidates, with the aim of demonstrating their suitability to become the first humans on Mars. The audience was to select one winner per region, and the experts could select additional participants, if needed, to continue to the international level.[needs update]
Round three takes place in 2016[needs update], over the course of 5 days. At the start of the event, the candidates organize themselves into groups of 105 men and 5 women of diverse nationalities and age groups.
The Mars One selection committee then sets up group dynamic challenges and provide study materials related to each challenge. This allow them to observe how the candidates work in a group setting and choose candidates for elimination.[needs update]
At the end of each day all the teams except the winner lose members; then they reorganize themselves for the following day. At the end 40 candidates remain.
The remaining 40 candidates are spending nine days in an isolation unit. The candidates are observed closely to examine how they act in situations of prolonged close contact with one another. This test is implemented because, during the journey to Mars and upon arrival, the candidates will spend 24 hours a day with each other and during this time the simplest things may start to become bothersome. It takes a specific team dynamic to be able to handle this, and the goal of this selection round is to find those that are best suited for this challenge.
After the isolation round, 30 candidates are chosen to partake in a Mars Settler Suitability Interview.
The Mars Settler Suitability Interview measures suitability for long duration Space missions and Mars settlement and will last approximately 4 hours. 24 candidates are selected after the interview and will be offered full-time employment with Mars One.
From the previous selection series, six groups of four are to become full-time employees of the Mars One astronaut corps, after which they are to train for the mission. Whole teams and individuals might be deselected during training if they prove not to be suitable for the mission. Six to ten teams of four people are to be selected for seven years of full-time training.
Mars One funding comes from private investment (undisclosed), intellectual property (IP) rights, the sale of future broadcasting rights, and astronaut application fees.
Mars One’s investment of revenues
Concept design studies (78.3%)
Travel expenses (11.6%)
Legal expenses (3.3%)
Website maintenance (2.4%)
Office and other (2.1%)
On January 29, 2013, Mars One announced its initial batch of investors from the Netherlands and South Africa. The value of the investment remains undisclosed.
Mars One initially estimated a one-way trip, excluding the cost of maintaining four astronauts on Mars until they die, at 6 billion USD. Lansdorp has declined questions regarding the cost estimate because he believes “it would be very stupid for us to give the prices that have been quoted per component”. For comparison, an “austere” manned Mars mission (including a temporary stay followed by a return of the astronauts) proposed by NASA in 2009 had a projected cost of $100 billion USD after an 18-year program, including a NASA-required return component.
Mars One, the not-for-profit foundation, is the controlling stockholder of the for-profit Interplanetary Media Group. A proposed global “reality-TV” media event was intended to provide funds to finance the expedition, however, no such reality TV show has emerged and no contracts have been signed. The astronaut selection process (with some public participation) was to be televised and continue on through the first years of living on Mars.
Discussions between Endemol, producers of the Big Brother series, and Mars One ended with Endemol subsidiary Darlow Smithson Productions issuing a statement in February 2015 that they “were unable to reach agreement on the details of the contract” and that the company was “no longer involved in the project.” Lansdorp updated plans to no longer include live broadcasts from Mars but instead rely on a documentary-style production, adding “Just like the Olympics, we watch highlights, we don’t watch things that athletes do when they’re not performing their abilities.”
On 31 August 2012, company officials announced that funding from its first sponsors had been received. Corporate sponsorship money will be used mostly to fund the conceptual design studies provided by the aerospace suppliers.
Since the official announcement of their conversion to a Stichting, Mars One has been accepting one-time and regular monthly donations through their website. As of 4 July 2016, Mars One had received $928,888 in donations and merchandise sales. The recent donation update adds the Indiegogo campaign ($313,744) to the private donation and merchandise total.
Over three quarters of the investment is in concept design studies. Mars One states that “income from donations and merchandise have not been used to pay salaries”. To date, no financial records have been released for public viewing.
On 10 December 2013, Mars One set up a crowdfunding campaign on Indiegogo to fund their 2018 demonstration mission. The 2018 mission includes a lander and communications satellite, and aims to prove several mission critical technologies in addition to launch and landing. The campaign goal was to raise $400,000 USD by 25 January 2014. Since the ending date was drawing near, they decided to extend the ending date to 9 February 2014. By the end of the campaign, they had received $313,744 in funds. Indiegogo will receive 9% ($28,237) of the $313,744 for the campaign failing to achieve its goal.
Mars One has identified at least one potential supplier for each component of the mission. The major components are planned to be acquired from proven suppliers. As of May 2013[update], Mars One has a contract with only one company, Paragon Space Development Corporation, for a preliminary life support study.
The Falcon Heavy from SpaceX was the notional launcher in the early Mars One conceptual plan, which included the notional use of SpaceX hardware for the lander and crew habitat, but, as of May 2013, SpaceX had not yet been contracted to supply mission hardware, and SpaceX has stated that it did “not currently have a relationship with Mars One.” By March 2014, SpaceX indicated that they had been contacted by Mars One, and were in discussions, but that accommodating Mars One requirements would require some additional work and that such work was not a part of the current focus of SpaceX.
A manned interplanetary spacecraft, which would transport the crew to Mars, would be assembled in low Earth orbit and comprise two propellant modules: a Transit Living Module (discarded just before arrival at Mars) and a lander (see “Human Lander” below).
A potential supplier for the Transit living module as of November 2012[update] was Thales Alenia Space.[non-primary source needed]
Contract has been signed with Lockheed Martin to build the Demo Lander with the same designs as the Phoenix lander that went to Mars.
In December 2013 Mars One awarded a contract to Surrey Satellite Technology for a study of the satellite technology required to provide 24/7 communication between Earth and the Mars base. Mars One proposed at least two satellites, one in areostationary orbit above Mars and a second at the Earth Sun L4 or L5 point to relay the signal when Mars blocks the areosynchronous satellite from line of sight to Earth. It is possible that a third satellite will be required to relay the signal on the rare occasions when the Sun blocks the first relay satellite from line of sight with Earth.
An early notional Mars One lander was shown in concept art as a 5 meters (16ft)-diameter variant of SpaceX’s Dragon capsule. SpaceX has not agreed for their technoogy to be used by the Mars One project.
The rover would be unpressurized and support travel distances of 80km (50 miles). A potential supplier for the rover as of November 2012[update] was Astrobotic Technology.[non-primary source needed]
The Mars suit would be flexible to allow the settlers to work with both cumbersome construction materials and sophisticated machinery when they are outside the habitat while protecting them from the cold, low pressure and noxious gases of the Martian atmosphere. The likely supplier of the suits is ILC Dover. On 12 March 2013, Paragon Space Development Corporation was contracted to develop concepts for life support and the Mars Surface Exploration Spacesuit System. The Paragon Space Development Corporation study was stated to be finished late summer 2013; Mars One released the results of this (ECLSS portion only) study to the public in June 2015. The Mars suit study portion of the original contract has just entered ITAR review, with a publicly accessible copy available once passed through review.
Mars One has received a variety of criticism, mostly relating to medical, technical and financial feasibility. There are also unverified claims that Mars One is a scam designed to take as much money as possible from donors, including reality show contestants. Many have criticized the project’s US$6 billion budget as being too low to successfully transport humans to Mars, to the point of being delusional. A similar project study by NASA estimated the cost of such a feat at US$100 billion, although that included transporting the astronauts back to Earth. Objections have also been raised regarding the reality TV project associated with the expedition. Given the transient nature of most reality TV ventures, many believe that as viewership declines, funding could significantly decrease, thereby harming the entire expedition. Further, TV reality show contestants have reported that they were ranked based on their donations and funds raised.
John Logsdon, a space policy expert at George Washington University, criticized the program, saying it appears to be a scam and not “a credible proposition”.
Chris Welch, director of Masters Programs at the International Space University, has said “Even ignoring the potential mismatch between the project income and its costs and questions about its longer-term viability, the Mars One proposal does not demonstrate a sufficiently deep understanding of the problems to give real confidence that the project would be able to meet its very ambitious schedule.”
Gerard ‘t Hooft, theoretical physicist and ambassador to Mars One, has stated that he thought both their proposed schedule and budget were off by a factor of ten. He said he still supported the project’s overall goals.
A space logistics analysis conducted by PhD candidates at the Massachusetts Institute of Technology revealed that the most optimistic of scenarios would require 15 Falcon Heavy launches that would cost approximately $4.5 billion. They concluded that the reliability of Environmental Control and Life Support systems (ECLS), the Technology Readiness Levels (TRL), and in situ resource utilization (ISRU) would have to be improved. Additionally, they determined that if the costs of launch were also lowered dramatically, together this would help to reduce the mass and cost of Mars settlement architecture. The environmental system would result in failure to be able to support human life in 68 days if fire safety standards on over-oxygenation were followed, due to excessive use of nitrogen supplies that would not then be able to be used to compensate leakage of air out of the habitat, leading to a resultant loss in pressurization, ending with pressures too low to support human life. Lansdorp replied that although he has not read all the research, supplier Lockheed Martin says that the technologies were viable.
Another serious concern uncovered in the research conducted by MIT is replacement parts. The PhD candidates estimated the need for spare parts in a Mars colony based on the failure rates of parts on the ISS. They determined that a resupply mission every two years would be necessary unless a large space in the initial launch were to be reserved for extra materials. Lansdorp commented on this saying, “They are correct. The major challenge of Mars One is keeping everything up and running. We don’t believe what we have designed is the best solution. It’s a good solution.”
In March 2015, one of the Mars One finalists, Joseph Roche, stated to media outlets that he believes the mission to be a scam. Roche holds doctorate degrees in physics and astrophysics, and shared many of his concerns and criticisms of the mission. These claims include that the organization lied about the number of applicants, stating that 200,000 individuals applied versus Roche’s claim of 2,761, and that many of the applicants had paid to be put on the list. Furthermore, Roche claimed that Mars One is asking finalists for donations from any money earned from guest appearances (which would amount to a minimal portion of the estimated $6 billion required for the mission). Finally, despite being one of 100 finalists, Roche himself has never spoken to any Mars One employee or representative in person, and instead of psychological or psychometric testing as is normal for astronaut candidates (especially for a lengthy, one-way mission), his interview process consisted of a 10-minute Skype conversation.
Robert Zubrin, advocate for manned Martian exploration, said “I don’t think the business plan closes it. We’re going to go to Mars, we need a billion dollars, and we’re going to make up the revenue with advertising and media rights and so on. You might be able to make up some of the money that way, but I don’t think that anyone who is interested in making money is going to invest on that basis invest in this really risky proposition, and if you’re lucky you’ll break even? That doesn’t fly.” Despite his criticisms, Zubrin became an adviser to Mars One on 10 October 2013.
Canadian former astronaut Julie Payette said during the opening speech for an International Civil Aviation Organization conference that she does not think Mars One “is sending anybody anywhere”.
In January 2014, German former astronaut Ulrich Walter strongly criticized the project for ethical reasons. Speaking with Tagesspiegel, he estimated the probability of reaching Mars alive at only 30%, and that of surviving there more than three months at less than 20%. He said, “They make their money with that [TV] show. They don’t care what happens to those people in space… If my tax money were used for such a mission, I would organize a protest.”
Space tourist Richard Garriott stated in response to Mars One, “Many have interesting viable starting plans. Few raise the money to be able to pull it off.”
Former astronaut Buzz Aldrin said in an interview that he wants to see humans on Mars by 2035, but he does not think Mars One will be the first to achieve it.
Wired magazine gave it a plausibility score of 2 out of 10 as part of their 2012 Most Audacious Private Space Exploration Plans.
The Daily Mail enumerated reasons why the project will never happen, calling the project “foolish”. The project lacks current funding as well as sources for future funding. The organization has no spacecraft or rocket in development or any contracts in place with companies that could provide a spacecraft or rocket. While plans point to SpaceX for both resources, the company has no contracts with Mars One in an industry that typically plans contracts decades in advance. The organization has not shared any research into the effects of microgravity on crews in flight or reduced gravity on the Mars surface. The organization has yet to provide plans or even study how crews might survive dust storms, supply challenges or the increased radiation on Mars.
Read the original here:
Mars One – Wikipedia
Posted: October 23, 2016 at 4:22 am
NATO (the North Atlantic Treaty Organization) is an international alliance that consists of 28 member states from North America and Europe. It was established at the signing of the North Atlantic Treaty on 4 April 1949. Article Five of the treaty states that if an armed attack occurs against one of the member states, it should be considered an attack against all members, and other members shall assist the attacked member, with armed forces if necessary.
Of the 28 member countries, two are located in North America (Canada and the United States) and 25 are European countries while Turkey is in Eurasia. All members have militaries, except for Iceland which does not have a typical army (but does, however, have a coast guard and a small unit of civilian specialists for NATO operations). Three of NATO’s members are nuclear weapons states: France, the United Kingdom, and the United States. NATO has 12 original founding member nation states, and from 18 February 1952 to 6 May 1955, it added 3 more member nations, and a fourth on 30 May 1982. After the end of the Cold War, NATO added 12 more member nations (10 former Warsaw Pact members and 2 former Yugoslav republics) from 12 March 1999 to 1 April 2009.
NATO has added new members six times since its founding in 1949, and since 2009 NATO has had 28 members. Twelve countries were part of the founding of NATO: Belgium, Canada, Denmark, France, Iceland, Italy, Luxembourg, the Netherlands, Norway, Portugal, the United Kingdom, and the United States. In 1952, Greece and Turkey became members of the Alliance, joined later by West Germany (in 1955) and Spain (in 1982). In 1990, with the reunification of Germany, NATO grew to include the former country of East Germany. Between 1994 and 1997, wider forums for regional cooperation between NATO and its neighbors were set up, including the Partnership for Peace, the Mediterranean Dialogue initiative and the Euro-Atlantic Partnership Council. In 1997, three former Warsaw Pact countries, Hungary, the Czech Republic, and Poland, were invited to join NATO. After this fourth enlargement in 1999, the Vilnius group of The Baltics and seven East European countries formed in May 2000 to cooperate and lobby for further NATO membership. Seven of these countries joined in the fifth enlargement in 2004. Albania and Croatia joined in the sixth enlargement in 2009.
Go here to see the original:
Member states of NATO – Wikipedia
Posted: October 20, 2016 at 11:35 pm
Immortality is eternal life, the ability to live forever.Natural selection has developed potential biological immortality in at least one species, Turritopsis dohrnii.
Certain scientists, futurists, and philosophers have theorized about the immortality of the human body (either through an immortal cell line researched or else deeper contextual understanding in advanced fields that have certain scope in the proposed long term reality that can be attained such as per mentioned in the reading of an article or scientific documentation of such a proposed idea would lead to), and advocate that human immortality is achievable in the first few decades of the 21st century, whereas other advocates believe that life extension is a more achievable goal in the short term, with immortality awaiting further research breakthroughs into an indefinite future. The absence of aging would provide humans with biological immortality, but not invulnerability to death by physical trauma; although mind uploading could solve that issue if it proved possible. Whether the process of internal endoimmortality would be delivered within the upcoming years depends chiefly on research (and in neuron research in the case of endoimmortality through an immortalized cell line) in the former view and perhaps is an awaited goal in the latter case.
In religious contexts, immortality is often stated to be one of the promises of God (or other deities) to human beings who show goodness or else follow divine law. What form an unending human life would take, or whether an immaterial soul exists and possesses immortality, has been a major point of focus of religion, as well as the subject of speculation, fantasy, and debate.
Life extension technologies promise a path to complete rejuvenation. Cryonics holds out the hope that the dead can be revived in the future, following sufficient medical advancements. While, as shown with creatures such as hydra and planarian worms, it is indeed possible for a creature to be biologically immortal, it is not known if it is possible for humans.
Mind uploading is the transference of brain states from a human brain to an alternative medium providing similar functionality. Assuming the process to be possible and repeatable, this would provide immortality to the computation of the original brain, as predicted by futurists such as Ray Kurzweil.
The belief in an afterlife is a fundamental tenet of most religions, including Hinduism, Buddhism, Jainism, Sikhism, Christianity, Zoroastrianism, Islam, Judaism, and the Bah’ Faith; however, the concept of an immortal soul is not. The “soul” itself has different meanings and is not used in the same way in different religions and different denominations of a religion. For example, various branches of Christianity have disagreeing views on the soul’s immortality and its relation to the body.
Physical immortality is a state of life that allows a person to avoid death and maintain conscious thought. It can mean the unending existence of a person from a physical source other than organic life, such as a computer. Active pursuit of physical immortality can either be based on scientific trends, such as cryonics, digital immortality, breakthroughs in rejuvenation or predictions of an impending technological singularity, or because of a spiritual belief, such as those held by Rastafarians or Rebirthers.
There are three main causes of death: aging, disease and physical trauma. Such issues can be resolved with the solutions provided in research to any end providing such alternate theories at present that require unification.
Aubrey de Grey, a leading researcher in the field, defines aging as “a collection of cumulative changes to the molecular and cellular structure of an adult organism, which result in essential metabolic processes, but which also, once they progress far enough, increasingly disrupt metabolism, resulting in pathology and death.” The current causes of aging in humans are cell loss (without replacement), DNA damage, oncogenic nuclear mutations and epimutations, cell senescence, mitochondrial mutations, lysosomal aggregates, extracellular aggregates, random extracellular cross-linking, immune system decline, and endocrine changes. Eliminating aging would require finding a solution to each of these causes, a program de Grey calls engineered negligible senescence. There is also a huge body of knowledge indicating that change is characterized by the loss of molecular fidelity.
Disease is theoretically surmountable via technology. In short, it is an abnormal condition affecting the body of an organism, something the body shouldn’t typically have to deal with its natural make up. Human understanding of genetics is leading to cures and treatments for myriad previously incurable diseases. The mechanisms by which other diseases do their damage are becoming better understood. Sophisticated methods of detecting diseases early are being developed. Preventative medicine is becoming better understood. Neurodegenerative diseases like Parkinson’s and Alzheimer’s may soon be curable with the use of stem cells. Breakthroughs in cell biology and telomere research are leading to treatments for cancer. Vaccines are being researched for AIDS and tuberculosis. Genes associated with type 1 diabetes and certain types of cancer have been discovered, allowing for new therapies to be developed. Artificial devices attached directly to the nervous system may restore sight to the blind. Drugs are being developed to treat a myriad of other diseases and ailments.
Physical trauma would remain as a threat to perpetual physical life, as an otherwise immortal person would still be subject to unforeseen accidents or catastrophes. The speed and quality of paramedic response remains a determining factor in surviving severe trauma. A body that could automatically repair itself from severe trauma, such as speculated uses for nanotechnology, would mitigate this factor. Being the seat of consciousness, the brain cannot be risked to trauma if a continuous physical life is to be maintained. This aversion to trauma risk to the brain would naturally result in significant behavioral changes that would render physical immortality undesirable.
Organisms otherwise unaffected by these causes of death would still face the problem of obtaining sustenance (whether from currently available agricultural processes or from hypothetical future technological processes) in the face of changing availability of suitable resources as environmental conditions change. After avoiding aging, disease, and trauma, you could still starve to death.
If there is no limitation on the degree of gradual mitigation of risk then it is possible that the cumulative probability of death over an infinite horizon is less than certainty, even when the risk of fatal trauma in any finite period is greater than zero. Mathematically, this is an aspect of achieving “actuarial escape velocity”
Biological immortality is an absence of aging, specifically the absence of a sustained increase in rate of mortality as a function of chronological age. A cell or organism that does not experience aging, or ceases to age at some point, is biologically immortal.
Biologists have chosen the word immortal to designate cells that are not limited by the Hayflick limit, where cells no longer divide because of DNA damage or shortened telomeres. The first and still most widely used immortal cell line is HeLa, developed from cells taken from the malignant cervical tumor of Henrietta Lacks without her consent in 1951. Prior to the 1961 work of Leonard Hayflick, there was the erroneous belief fostered by Alexis Carrel that all normal somatic cells are immortal. By preventing cells from reaching senescence one can achieve biological immortality; telomeres, a “cap” at the end of DNA, are thought to be the cause of cell aging. Every time a cell divides the telomere becomes a bit shorter; when it is finally worn down, the cell is unable to split and dies. Telomerase is an enzyme which rebuilds the telomeres in stem cells and cancer cells, allowing them to replicate an infinite number of times. No definitive work has yet demonstrated that telomerase can be used in human somatic cells to prevent healthy tissues from aging. On the other hand, scientists hope to be able to grow organs with the help of stem cells, allowing organ transplants without the risk of rejection, another step in extending human life expectancy. These technologies are the subject of ongoing research, and are not yet realized.
Life defined as biologically immortal is still susceptible to causes of death besides aging, including disease and trauma, as defined above. Notable immortal species include:
As the existence of biologically immortal species demonstrates, there is no thermodynamic necessity for senescence: a defining feature of life is that it takes in free energy from the environment and unloads its entropy as waste. Living systems can even build themselves up from seed, and routinely repair themselves. Aging is therefore presumed to be a byproduct of evolution, but why mortality should be selected for remains a subject of research and debate. Programmed cell death and the telomere “end replication problem” are found even in the earliest and simplest of organisms. This may be a tradeoff between selecting for cancer and selecting for aging.
Modern theories on the evolution of aging include the following:
There are some known naturally occurring and artificially produced chemicals that may increase the lifetime or life-expectancy of a person or organism, such as resveratrol.
Some scientists believe that boosting the amount or proportion of telomerase in the body, a naturally forming enzyme that helps maintain the protective caps at the ends of chromosomes, could prevent cells from dying and so may ultimately lead to extended, healthier lifespans. A team of researchers at the Spanish National Cancer Centre (Madrid) tested the hypothesis on mice. It was found that those mice which were genetically engineered to produce 10 times the normal levels of telomerase lived 50% longer than normal mice.
In normal circumstances, without the presence of telomerase, if a cell divides repeatedly, at some point all the progeny will reach their Hayflick limit. With the presence of telomerase, each dividing cell can replace the lost bit of DNA, and any single cell can then divide unbounded. While this unbounded growth property has excited many researchers, caution is warranted in exploiting this property, as exactly this same unbounded growth is a crucial step in enabling cancerous growth. If an organism can replicate its body cells faster, then it would theoretically stop aging.
Embryonic stem cells express telomerase, which allows them to divide repeatedly and form the individual. In adults, telomerase is highly expressed in cells that need to divide regularly (e.g., in the immune system), whereas most somatic cells express it only at very low levels in a cell-cycle dependent manner.
Technological immortality is the prospect for much longer life spans made possible by scientific advances in a variety of fields: nanotechnology, emergency room procedures, genetics, biological engineering, regenerative medicine, microbiology, and others. Contemporary life spans in the advanced industrial societies are already markedly longer than those of the past because of better nutrition, availability of health care, standard of living and bio-medical scientific advances. Technological immortality predicts further progress for the same reasons over the near term. An important aspect of current scientific thinking about immortality is that some combination of human cloning, cryonics or nanotechnology will play an essential role in extreme life extension. Robert Freitas, a nanorobotics theorist, suggests tiny medical nanorobots could be created to go through human bloodstreams, find dangerous things like cancer cells and bacteria, and destroy them. Freitas anticipates that gene-therapies and nanotechnology will eventually make the human body effectively self-sustainable and capable of living indefinitely in empty space, short of severe brain trauma. This supports the theory that we will be able to continually create biological or synthetic replacement parts to replace damaged or dying ones. Future advances in nanomedicine could give rise to life extension through the repair of many processes thought to be responsible for aging. K. Eric Drexler, one of the founders of nanotechnology, postulated cell repair devices, including ones operating within cells and utilizing as yet hypothetical biological machines, in his 1986 book Engines of Creation. Raymond Kurzweil, a futurist and transhumanist, stated in his book The Singularity Is Near that he believes that advanced medical nanorobotics could completely remedy the effects of aging by 2030. According to Richard Feynman, it was his former graduate student and collaborator Albert Hibbs who originally suggested to him (circa 1959) the idea of a medical use for Feynman’s theoretical micromachines (see nanobiotechnology). Hibbs suggested that certain repair machines might one day be reduced in size to the point that it would, in theory, be possible to (as Feynman put it) “swallow the doctor”. The idea was incorporated into Feynman’s 1959 essay There’s Plenty of Room at the Bottom.
Cryonics, the practice of preserving organisms (either intact specimens or only their brains) for possible future revival by storing them at cryogenic temperatures where metabolism and decay are almost completely stopped, can be used to ‘pause’ for those who believe that life extension technologies will not develop sufficiently within their lifetime. Ideally, cryonics would allow clinically dead people to be brought back in the future after cures to the patients’ diseases have been discovered and aging is reversible. Modern cryonics procedures use a process called vitrification which creates a glass-like state rather than freezing as the body is brought to low temperatures. This process reduces the risk of ice crystals damaging the cell-structure, which would be especially detrimental to cell structures in the brain, as their minute adjustment evokes the individual’s mind.
One idea that has been advanced involves uploading an individual’s habits and memories via direct mind-computer interface. The individual’s memory may be loaded to a computer or to a new organic body. Extropian futurists like Moravec and Kurzweil have proposed that, thanks to exponentially growing computing power, it will someday be possible to upload human consciousness onto a computer system, and exist indefinitely in a virtual environment. This could be accomplished via advanced cybernetics, where computer hardware would initially be installed in the brain to help sort memory or accelerate thought processes. Components would be added gradually until the person’s entire brain functions were handled by artificial devices, avoiding sharp transitions that would lead to issues of identity, thus running the risk of the person to be declared dead and thus not be a legitimate owner of his or her property. After this point, the human body could be treated as an optional accessory and the program implementing the person could be transferred to any sufficiently powerful computer. Another possible mechanism for mind upload is to perform a detailed scan of an individual’s original, organic brain and simulate the entire structure in a computer. What level of detail such scans and simulations would need to achieve to emulate awareness, and whether the scanning process would destroy the brain, is still to be determined. Whatever the route to mind upload, persons in this state could then be considered essentially immortal, short of loss or traumatic destruction of the machines that maintained them.[clarification needed]
Transforming a human into a cyborg can include brain implants or extracting a human processing unit and placing it in a robotic life-support system. Even replacing biological organs with robotic ones could increase life span (i.e., pace makers) and depending on the definition, many technological upgrades to the body, like genetic modifications or the addition of nanobots would qualify an individual as a cyborg. Some people believe that such modifications would make one impervious to aging and disease and theoretically immortal unless killed or destroyed.
Another approach, developed by biogerontologist Marios Kyriazis, holds that human biological immortality is an inevitable consequence of evolution. As the natural tendency is to create progressively more complex structures, there will be a time (Kyriazis claims this time is now), when evolution of a more complex human brain will be faster via a process of developmental singularity rather than through Darwinian evolution. In other words, the evolution of the human brain as we know it will cease and there will be no need for individuals to procreate and then die. Instead, a new type of development will take over, in the same individual who will have to live for many centuries in order for the development to take place. This intellectual development will be facilitated by technology such as synthetic biology, artificial intelligence and a technological singularity process.
As late as 1952, the editorial staff of the Syntopicon found in their compilation of the Great Books of the Western World, that “The philosophical issue concerning immortality cannot be separated from issues concerning the existence and nature of man’s soul.” Thus, the vast majority of speculation regarding immortality before the 21st century was regarding the nature of the afterlife.
Immortality in ancient Greek religion originally always included an eternal union of body and soul as can be seen in Homer, Hesiod, and various other ancient texts. The soul was considered to have an eternal existence in Hades, but without the body the soul was considered dead. Although almost everybody had nothing to look forward to but an eternal existence as a disembodied dead soul, a number of men and women were considered to have gained physical immortality and been brought to live forever in either Elysium, the Islands of the Blessed, heaven, the ocean or literally right under the ground. Among these were Amphiaraus, Ganymede, Ino, Iphigenia, Menelaus, Peleus, and a great part of those who fought in the Trojan and Theban wars. Some were considered to have died and been resurrected before they achieved physical immortality. Asclepius was killed by Zeus only to be resurrected and transformed into a major deity. In some versions of the Trojan War myth, Achilles, after being killed, was snatched from his funeral pyre by his divine mother Thetis, resurrected, and brought to an immortal existence in either Leuce, the Elysian plains, or the Islands of the Blessed. Memnon, who was killed by Achilles, seems to have received a similar fate. Alcmene, Castor, Heracles, and Melicertes were also among the figures sometimes considered to have been resurrected to physical immortality. According to Herodotus’ Histories, the 7th century BC sage Aristeas of Proconnesus was first found dead, after which his body disappeared from a locked room. Later he was found not only to have been resurrected but to have gained immortality.
The philosophical idea of an immortal soul was a belief first appearing with either Pherecydes or the Orphics, and most importantly advocated by Plato and his followers. This, however, never became the general norm in Hellenistic thought. As may be witnessed even into the Christian era, not least by the complaints of various philosophers over popular beliefs, many or perhaps most traditional Greeks maintained the conviction that certain individuals were resurrected from the dead and made physically immortal and that others could only look forward to an existence as disembodied and dead, though everlasting, souls. The parallel between these traditional beliefs and the later resurrection of Jesus was not lost on the early Christians, as Justin Martyr argued: “when we say… Jesus Christ, our teacher, was crucified and died, and rose again, and ascended into heaven, we propose nothing different from what you believe regarding those whom you consider sons of Zeus.” (1 Apol. 21).
The goal of Hinayana is Arhatship and Nirvana. By contrast, the goal of Mahayana is Buddhahood.
According to one Tibetan Buddhist teaching, Dzogchen, individuals can transform the physical body into an immortal body of light called the rainbow body.
Christian theology holds that Adam and Eve lost physical immortality for themselves and all their descendants in the Fall of Man, although this initial “imperishability of the bodily frame of man” was “a preternatural condition”. Christians who profess the Nicene Creed believe that every dead person (whether they believed in Christ or not) will be resurrected from the dead at the Second Coming, and this belief is known as Universal resurrection.
N.T. Wright, a theologian and former Bishop of Durham, has said many people forget the physical aspect of what Jesus promised. He told Time: “Jesus’ resurrection marks the beginning of a restoration that he will complete upon his return. Part of this will be the resurrection of all the dead, who will ‘awake’, be embodied and participate in the renewal. Wright says John Polkinghorne, a physicist and a priest, has put it this way: ‘God will download our software onto his hardware until the time he gives us new hardware to run the software again for ourselves.’ That gets to two things nicely: that the period after death (the Intermediate state) is a period when we are in God’s presence but not active in our own bodies, and also that the more important transformation will be when we are again embodied and administering Christ’s kingdom.” This kingdom will consist of Heaven and Earth “joined together in a new creation”, he said.
Hindus believe in an immortal soul which is reincarnated after death. According to Hinduism, people repeat a process of life, death, and rebirth in a cycle called samsara. If they live their life well, their karma improves and their station in the next life will be higher, and conversely lower if they live their life poorly. After many life times of perfecting its karma, the soul is freed from the cycle and lives in perpetual bliss. There is no place of eternal torment in Hinduism, although if a soul consistently lives very evil lives, it could work its way down to the very bottom of the cycle.
There are explicit renderings in the Upanishads alluding to a physically immortal state brought about by purification, and sublimation of the 5 elements that make up the body. For example, in the Shvetashvatara Upanishad (Chapter 2, Verse 12), it is stated “When earth, water fire, air and akasa arise, that is to say, when the five attributes of the elements, mentioned in the books on yoga, become manifest then the yogi’s body becomes purified by the fire of yoga and he is free from illness, old age and death.” This phenomenon is possible when the soul reaches enlightenment while the body and mind are still intact, an extreme rarity, and can only be achieved upon the highest most dedication, meditation and consciousness.
Another view of immortality is traced to the Vedic tradition by the interpretation of Maharishi Mahesh Yogi:
That man indeed whom these (contacts) do not disturb, who is even-minded in pleasure and pain, steadfast, he is fit for immortality, O best of men.
To Maharishi Mahesh Yogi, the verse means, “Once a man has become established in the understanding of the permanent reality of life, his mind rises above the influence of pleasure and pain. Such an unshakable man passes beyond the influence of death and in the permanent phase of life: he attains eternal life… A man established in the understanding of the unlimited abundance of absolute existence is naturally free from existence of the relative order. This is what gives him the status of immortal life.”
An Indian Tamil saint known as Vallalar claimed to have achieved immortality before disappearing forever from a locked room in 1874.
Many Indian fables and tales include instances of metempsychosisthe ability to jump into another bodyperformed by advanced Yogis in order to live a longer life.
The traditional concept of an immaterial and immortal soul distinct from the body was not found in Judaism before the Babylonian Exile, but developed as a result of interaction with Persian and Hellenistic philosophies. Accordingly, the Hebrew word nephesh, although translated as “soul” in some older English Bibles, actually has a meaning closer to “living being”.Nephesh was rendered in the Septuagint as (psch), the Greek word for soul.
The only Hebrew word traditionally translated “soul” (nephesh) in English language Bibles refers to a living, breathing conscious body, rather than to an immortal soul. In the New Testament, the Greek word traditionally translated “soul” () has substantially the same meaning as the Hebrew, without reference to an immortal soul. Soul may refer to the whole person, the self: three thousand souls were converted in Acts 2:41 (see Acts 3:23).
The Hebrew Bible speaks about Sheol (), originally a synonym of the grave-the repository of the dead or the cessation of existence until the Resurrection. This doctrine of resurrection is mentioned explicitly only in Daniel 12:14 although it may be implied in several other texts. New theories arose concerning Sheol during the intertestamental literature.
The views about immortality in Judaism is perhaps best exemplified by the various references to this in Second Temple Period. The concept of resurrection of the physical body is found in 2 Maccabees, according to which it will happen through recreation of the flesh. Resurrection of the dead also appears in detail in the extra-canonical books of Enoch, and in Apocalypse of Baruch. According to the British scholar in ancient Judaism Philip R. Davies, there is little or no clear reference either to immortality or to resurrection from the dead in the Dead Sea scrolls texts. Both Josephus and the New Testament record that the Sadducees did not believe in an afterlife, but the sources vary on the beliefs of the Pharisees. The New Testament claims that the Pharisees believed in the resurrection, but does not specify whether this included the flesh or not. According to Josephus, who himself was a Pharisee, the Pharisees held that only the soul was immortal and the souls of good people will be reincarnated and pass into other bodies, while the souls of the wicked will suffer eternal punishment. Jubilees seems to refer to the resurrection of the soul only, or to a more general idea of an immortal soul.
Rabbinic Judaism claims that the righteous dead will be resurrected in the Messianic age with the coming of the messiah. They will then be granted immortality in a perfect world. The wicked dead, on the other hand, will not be resurrected at all. This is not the only Jewish belief about the afterlife. The Tanakh is not specific about the afterlife, so there are wide differences in views and explanations among believers.
It is repeatedly stated in Lshi Chunqiu that death is unavoidable.Henri Maspero noted that many scholarly works frame Taoism as a school of thought focused on the quest for immortality. Isabelle Robinet asserts that Taoism is better understood as a way of life than as a religion, and that its adherents do not approach or view Taoism the way non-Taoist historians have done. In the Tractate of Actions and their Retributions, a traditional teaching, spiritual immortality can be rewarded to people who do a certain amount of good deeds and live a simple, pure life. A list of good deeds and sins are tallied to determine whether or not a mortal is worthy. Spiritual immortality in this definition allows the soul to leave the earthly realms of afterlife and go to pure realms in the Taoist cosmology.
Zoroastrians believe that on the fourth day after death, the human soul leaves the body and the body remains as an empty shell. Souls would go to either heaven or hell; these concepts of the afterlife in Zoroastrianism may have influenced Abrahamic religions. The Persian word for “immortal” is associated with the month “Amurdad”, meaning “deathless” in Persian, in the Iranian calendar (near the end of July). The month of Amurdad or Ameretat is celebrated in Persian culture as ancient Persians believed the “Angel of Immortality” won over the “Angel of Death” in this month.
The possibility of clinical immortality raises a host of medical, philosophical, and religious issues and ethical questions. These include persistent vegetative states, the nature of personality over time, technology to mimic or copy the mind or its processes, social and economic disparities created by longevity, and survival of the heat death of the universe.
The Epic of Gilgamesh, one of the first literary works, is primarily a quest of a hero seeking to become immortal.
Physical immortality has also been imagined as a form of eternal torment, as in Mary Shelley’s short story “The Mortal Immortal”, the protagonist of which witnesses everyone he cares about dying around him. Jorge Luis Borges explored the idea that life gets its meaning from death in the short story “The Immortal”; an entire society having achieved immortality, they found time becoming infinite, and so found no motivation for any action. In his book “Thursday’s Fictions”, and the stage and film adaptations of it, Richard James Allen tells the story of a woman named Thursday who tries to cheat the cycle of reincarnation to get a form of eternal life. At the end of this fantastical tale, her son, Wednesday, who has witnessed the havoc his mother’s quest has caused, forgoes the opportunity for immortality when it is offered to him. Likewise, the novel Tuck Everlasting depicts immortality as “falling off the wheel of life” and is viewed as a curse as opposed to a blessing. In the anime Casshern Sins humanity achieves immortality due to advances in medical technology, however the inability of the human race to die causes Luna, a Messianic figure, to come forth and offer normal lifespans because she had believed that without death, humans could not live. Ultimately, Casshern takes up the cause of death for humanity when Luna begins to restore humanity’s immortality. In Anne Rice’s book series “The Vampire Chronicles”, vampires are portrayed as immortal and ageless, but their inability to cope with the changes in the world around them means that few vampires live for much more than a century, and those who do often view their changeless form as a curse.
Although some scientists state that radical life extension, delaying and stopping aging are achievable, there are no international or national programs focused on stopping aging or on radical life extension. In 2012 in Russia, and then in the United States, Israel and the Netherlands, pro-immortality political parties were launched. They aimed to provide political support to anti-aging and radical life extension research and technologies and at the same time transition to the next step, radical life extension, life without aging, and finally, immortality and aim to make possible access to such technologies to most currently living people.
There are numerous symbols representing immortality. The ankh is an Egyptian symbol of life that holds connotations of immortality when depicted in the hands of the gods and pharaohs, who were seen as having control over the journey of life. The Mbius strip in the shape of a trefoil knot is another symbol of immortality. Most symbolic representations of infinity or the life cycle are often used to represent immortality depending on the context they are placed in. Other examples include the Ouroboros, the Chinese fungus of longevity, the ten kanji, the phoenix, the peacock in Christianity, and the colors amaranth (in Western culture) and peach (in Chinese culture).
Immortal species abound in fiction, especially in fantasy literature.